TREATMENT READING
Prostate Cancer
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
137 sections
- Follow-Up After Treatment
- Follow-up after radical prostatectomy
- Follow-up after radiation therapy
- Follow-up after hormonal therapy
- Treatment Option Overview for Prostate Cancer
- Watchful Waiting or Active Surveillance/Active Monitoring
- Radical Prostatectomy
- Radical prostatectomy compared with other treatment options
- Complications of radical prostatectomy
- Morbidity and mortality associated with radical prostatectomy
- Urinary incontinence and impotence
- Penile shortening
- Inguinal hernia
- Fecal incontinence
- Radiation Therapy and Radiopharmaceutical Therapy
- External-beam radiation therapy (EBRT)
- Conventional versus hypofractionated EBRT
- Brachytherapy
- Radiopharmaceutical therapy
- Alpha emitter radiation
- Complications of radiation therapy
- Reducing complications
- Comparison of complications from radiation therapy and from radical prostatectomy
- Hormonal Therapy and Its Complications
- Abiraterone acetate
- Bilateral orchiectomy
- Estrogen therapy
- Luteinizing hormone-releasing hormone (LH-RH) agonist therapy
- Antiandrogen therapy
- ADT
- Antiadrenal therapy
- Cryosurgery
- Proton-Beam Therapy
- Photodynamic Therapy
- Neoadjuvant Hormonal Therapy
- Bicalutamide
- Treatment of Stage I Prostate Cancer
- Overview
- Treatment Options for Stage I Prostate Cancer
- Watchful waiting or active surveillance/active monitoring
- Radical prostatectomy
- External-beam radiation therapy (EBRT)
- Interstitial implantation of radioisotopes
- Photodynamic therapy
- Treatment of Stage II Prostate Cancer
- Overview
- Prostate-specific antigen (PSA) changes as markers of tumor progression
- Bisphosphonates and risk of bone metastases
- Treatment Options for Stage II Prostate Cancer
- Watchful waiting or active surveillance/active monitoring
- Radical prostatectomy
- External-beam radiation therapy (EBRT) with or without hormonal therapy
- Interstitial implantation of radioisotopes
- Ultrasound-guided percutaneous cryosurgery
- High-intensity focused ultrasound
- Proton-beam radiation therapy
- Photodynamic therapy
- Treatment of Stage III Prostate Cancer
- Overview
- Treatment Options for Stage III Prostate Cancer
- External-beam radiation therapy (EBRT) with or without hormonal therapy
- Hormonal manipulations (with or without radiation therapy)
- Immediate versus deferred hormonal therapy
- Continuous versus intermittent hormonal therapy
- Radical prostatectomy with or without EBRT
- Watchful waiting or active surveillance/active monitoring
- Treatment of Symptoms
- Radiation therapy
- Hormonal manipulation
- Interstitial implantation combined with EBRT
- Alternative forms of radiation therapy
- Ultrasound-guided percutaneous cryosurgery
- Treatment of Stage IV Prostate Cancer
- Overview
- Treatment Options for Stage IV Prostate Cancer
- Hormonal manipulations
- Immediate versus deferred hormonal therapy
- Luteinizing hormone-releasing hormone (LH-RH) agonists or antiandrogens
- Maximal androgen blockade (MAB)
- Continuous versus intermittent hormonal therapy
- Hormonal manipulations with chemotherapy
- Bisphosphonates
- Bisphosphonates and decreasing risk of bone metastases
- External-beam radiation therapy (EBRT) with or without hormonal therapy
- Palliative radiation therapy
- Palliative surgery with transurethral resection of the prostate (TURP)
- Watchful waiting or active surveillance/active monitoring
- Radical prostatectomy with immediate orchiectomy
- Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer
- Overview
- Immediate Versus Deferred Hormonal Therapy
- Hormonal Therapy for Recurring Disease
- Continuous versus intermittent hormonal therapy
- Nonsteroidal antiandrogen therapy with or without androgen deprivation therapy
- Nonsteroidal antiandrogen monotherapy versus surgical or medical castration
- Hormonal approaches
- Prevention of bone metastases
- Treatment Options for Recurrent Prostate Cancer
- Chemotherapy for hormone-sensitive or hormone-resistant prostate cancer
- Immunotherapy
- Radiopharmaceutical therapy
- Alpha emitter radiation therapy
- Beta emitter radiation therapy
- PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants
- Olaparib
- Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants
- PARP inhibitors as first-line therapy for men with mCRPC and BRCA1 or BRCA2 variants
- PARP inhibitors as first-line therapy for men with mCRPC and variants in homologous recombination repair genes
- Certain factors affect prognosis (chance of recovery) and treatment options.
- Prostate cancer may recur (come back) after it has been treated.
- Treatment Option Overview
- Key Points
- There are different types of treatment for people with prostate cancer.
- The following types of treatment are used:
- Watchful waiting or active surveillance
- Surgery
- Radiation therapy and radiopharmaceutical therapy
- Hormone therapy
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Bisphosphonate therapy
- There are treatments for bone pain caused by bone metastases or hormone therapy.
- New types of treatment are being tested in clinical trials.
- Cryosurgery
- High-intensity focused ultrasound therapy
- Proton beam radiation therapy
- Photodynamic therapy
- Treatment for prostate cancer may cause side effects.
- Patients may want to think about taking part in a clinical trial.
- Patients can enter clinical trials before, during, or after starting their cancer treatment.
- Follow-up care may be needed.
- Treatment of Stage I Prostate Cancer
- Treatment of Stage II Prostate Cancer
- Treatment of Stage III Prostate Cancer
- Treatment of Stage IV Prostate Cancer
- Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer
Follow-Up After Treatment
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The optimal follow-up strategy for men treated for prostate cancer is uncertain. Men should be interviewed and examined for symptoms or signs of recurrent or progressing disease, as well as side effects of therapy that can be managed by changes in therapy. However, using surrogate end points for clinical decision-making is controversial, and the evidence that changing therapy based on such end points translates into clinical benefit is weak. Often, rates of PSA change are thought to be markers of tumor progression. However, even though a tumor marker or characteristic may be consistently associated with a high risk of prostate cancer progression or death, it may be a poor predictor and of limited utility in making therapeutic decisions.
Although the PSA test is nearly universally used to follow patients, the diversity of recommendations on follow-up care reflects the lack of research evidence on which to base firm conclusions. A systematic review of international guidelines highlights the need for robust primary research to inform future evidence-based models of follow-up care for men with prostate cancer.[53]
Sources: 53
Preliminary data from a retrospective cohort of 8,669 patients with clinically localized prostate cancer treated with either radical prostatectomy or radiation therapy suggested that short posttreatment PSA doubling time (<3 months in this study) fulfills some criteria as a surrogate end point for all-cause mortality and prostate cancer-specific mortality after surgery or radiation therapy.[54]
Sources: 54
Likewise, a retrospective analysis (SWOG-S9916 [NCT00004001]) showed PSA declines of 20% to 40% (but not 50%) at 3 months and 30% or more at 2 months after initiation of chemotherapy for hormone-independent prostate cancer, and fulfilled several criteria of surrogacy for overall survival (OS).[55]
Sources: SWOG-S9916 · 55
These observations should be independently confirmed in prospective study designs and may not apply to patients treated with hormonal therapy. In addition, there are no standardized criteria of surrogacy or standardized cut points for adequacy of surrogate end points, even in prospective trials.[56]
Sources: 56
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Follow-up after radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
After radical prostatectomy, a detectable PSA level identifies patients at elevated risk of local treatment failure or metastatic disease;[37] however, a substantial proportion of patients with an elevated or rising PSA level after surgery remain clinically free of symptoms for extended periods.[57] Biochemical evidence of failure on the basis of elevated or slowly rising PSA alone, therefore, may not be sufficient to initiate additional treatment.
For example, in a retrospective analysis of nearly 2,000 men who had undergone radical prostatectomy with curative intent and were followed for a mean of 5.3 years, 315 men (15%) demonstrated an abnormal PSA of 0.2 ng/mL or higher, which is considered evidence of biochemical recurrence. Among these 315 men, 103 (34%) developed clinical evidence of recurrence. The median time to the development of clinical metastasis after biochemical recurrence was 8 years. After the men developed metastatic disease, the median time to death was an additional 5 years.[58]
Sources: 58
Follow-up after radiation therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
For patients treated with radiation therapy, the combination of clinical tumor stage, Gleason score, and pretreatment PSA level is often used to estimate the risk of relapse.[59][Level of evidence C2] As is the case after prostatectomy, PSA is often followed for signs of tumor recurrence after radiation therapy. After radiation therapy with curative intent, persistently elevated or rising PSA may be a prognostic factor for clinical disease recurrence; however, reported case series have used a variety of definitions of PSA failure. The American Society for Therapeutic Radiology and Oncology Consensus Panel has developed criteria.[60,61] It is difficult to base decisions about initiating additional therapy on biochemical failure alone. The implication of the various definitions of PSA failure for OS is not known, and, as in the surgical series, many biochemical relapses (rising PSA only) may not be clinically manifested in patients treated with radiation therapy.[62,63]
Follow-up after hormonal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
After hormonal therapy, reduction of PSA to undetectable levels provides information regarding the duration of progression-free status; however, decreases in PSA of less than 80% may not be predictive.[32] Because PSA expression itself is under hormonal control, androgen deprivation therapy can decrease the serum level of PSA independent of tumor response. Clinicians, therefore, cannot rely solely on the serum PSA level to monitor a patient’s response to hormonal therapy; they must also follow clinical criteria.[64]
Treatment Option Overview for Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Local treatment modalities are associated with prolonged disease-free survival (DFS) for many patients with localized prostate cancer but are rarely curative in patients with locally extensive tumors. Because of clinical understaging using current diagnostic techniques, even when the cancer appears clinically localized to the prostate gland, some patients develop disseminated tumors after local therapy with surgery or radiation.
Treatment options for each stage of prostate cancer are presented in Table 6.
Sources: Table 6
| Stage (TNM Definitions) | Treatment Options |
|---|---|
| EBRT = external-beam radiation therapy; LH-RH = luteinizing hormone-releasing hormone; mCRPC = metastatic castration-resistant prostate cancer; PARP = poly (ADP-ribose) polymerase; TURP = transurethral resection of the prostate. | |
| Stage I Prostate Cancer | Watchful waiting or active surveillance/active monitoring |
| Radical prostatectomy | |
| External-beam radiation therapy (EBRT) | |
| Interstitial implantation of radioisotopes | |
| Photodynamic therapy (under clinical evaluation) | |
| Bicalutamide (under clinical evaluation) | |
| Stage II Prostate Cancer | Watchful waiting or active surveillance/active monitoring |
| Radical prostatectomy | |
| EBRT with or without hormonal therapy | |
| Interstitial implantation of radioisotopes | |
| Cryosurgery (under clinical evaluation) | |
| Proton-beam therapy (under clinical evaluation) | |
| Photodynamic therapy (under clinical evaluation) | |
| Neoadjuvant hormonal therapy (under clinical evaluation) | |
| Bicalutamide (under clinical evaluation) | |
| Stage III Prostate Cancer | EBRT with or without hormonal therapy |
| Hormonal manipulations with or without radiation therapy | |
| Radical prostatectomy with or without EBRT | |
| Watchful waiting or active surveillance/active monitoring | |
| Cryosurgery (under clinical evaluation) | |
| Proton-beam therapy (under clinical evaluation) | |
| Bicalutamide (under clinical evaluation) | |
| Stage IV Prostate Cancer | Hormonal manipulations |
| Bisphosphonates | |
| EBRT with or without hormonal therapy | |
| Palliative radiation therapy | |
| Palliative surgery with transurethral resection of the prostate (TURP) | |
| Watchful waiting or active surveillance/active monitoring | |
| Recurrent Prostate Cancer | Chemotherapy for hormone-sensitive or hormone-resistant prostate cancer |
| Immunotherapy | |
| Radiopharmaceutical therapy | |
| PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants | |
| Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants | |
Sources: TNM Definitions · Watchful waiting or active surveillance/active monitoring · Radical prostatectomy · External-beam radiation therapy (EBRT) · Interstitial implantation of radioisotopes · Photodynamic therapy · Bicalutamide · Watchful waiting or active surveillance/active monitoring · Radical prostatectomy · EBRT with or without hormonal therapy · Interstitial implantation of radioisotopes · Cryosurgery · Proton-beam therapy · Photodynamic therapy · Neoadjuvant hormonal therapy · Bicalutamide · EBRT with or without hormonal therapy · Hormonal manipulations with or without radiation therapy · Radical prostatectomy with or without EBRT · Watchful waiting or active surveillance/active monitoring · Cryosurgery · Proton-beam therapy · Bicalutamide · Hormonal manipulations · Bisphosphonates · EBRT with or without hormonal therapy · Palliative radiation therapy · Palliative surgery with transurethral resection of the prostate (TURP) · Watchful waiting or active surveillance/active monitoring · Chemotherapy for hormone-sensitive or hormone-resistant prostate cancer · Immunotherapy · Radiopharmaceutical therapy · PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants · Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants
Side effects of each treatment approach are covered in the relevant sections below. Patient-reported adverse effects differ substantially across the options for management of clinically localized disease, with few direct comparisons, and include watchful waiting/active surveillance/active monitoring, radical prostatectomy, and radiation therapy. The differences in adverse effects can play an important role in patient choice among treatment options. Detailed comparisons of these effects have been reported in population-based cohort studies, albeit with relatively short follow-up times of 2 to 3 years.[1,2]
Watchful Waiting or Active Surveillance/Active Monitoring
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Asymptomatic patients of advanced age or with concomitant illness may warrant careful observation without immediate active treatment.[3,4] Watch and wait, observation, expectant management, and active surveillance/active monitoring are terms indicating a strategy that does not employ immediate therapy with curative intent.
Watchful waiting and active surveillance/active monitoring are the most commonly used terms, and the literature does not always clearly distinguish them, making the interpretation of results difficult. The general concept of watchful waiting is patient follow-up with the application of palliative care as needed to alleviate symptoms of tumor progression. There is no planned attempt at curative therapy at any point in follow-up. For example, transurethral resection of the prostate (TURP) or hormonal therapy may be used to alleviate tumor-related urethral obstruction should there be local tumor growth; hormonal therapy or bone radiation might be used to alleviate pain from metastases. Radical prostatectomy has been compared with watchful waiting or active surveillance/active monitoring in men with early-stage disease (i.e., clinical stages T1b, T1c, or T2).[5] For more information, see the Radical Prostatectomy section.
Sources: 5 · Radical Prostatectomy
In contrast, the strategy behind active surveillance/active monitoring is to defer therapy for clinically localized disease but regularly follow the patient and initiate local therapy with curative intent if there are any signs of local tumor progression.[6-9] The intention is to avoid the morbidity of therapy in men who have indolent or nonprogressive disease but preserve the ability to cure them should the tumor progress. Active surveillance/active monitoring often involves:
Regular patient visits.
Digital rectal examinations.
Prostate-specific antigen (PSA) testing.
Transrectal ultrasound (in some series).
Transrectal needle biopsies (in some series).
Patient selection, testing intervals, and specific tests, as well as criteria for intervention, are arbitrary and not established in controlled trials.
In the United States, as in other settings with widespread PSA screening, the results of conservative management of localized prostate cancer are particularly favorable. In the aggregate, men managed by watchful waiting or active surveillance/active monitoring (using various criteria, depending upon the study) have had very favorable prostate–cancer-specific mortalities ranging from about 1% to 10% (with the most favorable rates in more recent series).[10-18] Most men with screen-detected prostate cancer may, therefore, be candidates for active surveillance/active monitoring, with definitive therapy reserved for signs of tumor progression. This has been shown most clearly in the large Prostate Testing for Cancer Treatment (ProtecT [NCT02044172 and ISRCTN20141297]) randomized trial that compared active monitoring, radical prostatectomy, and radiation therapy.[19] For more information, see the Radical Prostatectomy section.
Sources: 10 · 18 · ProtecT · 19 · Radical Prostatectomy
For more information, see the Treatment of Stage II Prostate Cancer section.
Radical Prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Are in good health and elect surgical intervention.
Have tumor confined to the prostate gland (stage I and stage II).
Open prostatectomy can be performed by the perineal or retropubic approach. The perineal approach requires a separate incision for lymph node dissection. Laparoscopic lymphadenectomy is technically possible.[23] Robot-assisted prostatectomy is an alternative to open prostatectomy and has become the most common technique in developed countries. In experienced hands, functional outcomes between open and robot-assisted prostatectomy appear very similar, at least in the short- to mid-term. In a randomized trial of 308 men suitable for prostatectomy, urinary, sexual, and bowel functional outcomes were similar between open retropubic and robotic surgeries at a median follow-up of 24 months.[24] The sample size and duration of follow-up were too small to detect meaningful differences in cancer outcomes.
For small, well-differentiated nodules, the incidence of positive pelvic nodes is less than 20%, and pelvic node dissection may be omitted.[25] With larger, less-differentiated tumors, a pelvic lymph node dissection is more important. In these cases, the value of open surgical or laparoscopic pelvic node dissection is not therapeutic, but it spares patients with positive nodes the morbidity of prostatectomy. Radical prostatectomy is usually not performed if a frozen-section evaluation of pelvic nodes reveals metastases; these patients should be considered for entry into existing clinical trials or receive radiation therapy to control local symptoms.
Sources: 25
After radical prostatectomy, pathological evaluation stratifies tumor extent into the following classes:
Margin-positive disease—The incidence of disease recurrence increases when the tumor margins are positive.[10,28,29] Results of the outcome of patients with positive surgical margins have not been systematically reported.
Specimen-confined disease—The incidence of disease recurrence increases when the tumor is not specimen-confined (extracapsular).[10,28]
Organ-confined disease—Patients with extraprostatic disease (not organ-confined) are suitable candidates for clinical trials of which the Radiation Therapy Oncology Group's (RTOG) RTOG-9601 trial (NCT00002874), was an example. These trials have included evaluation of postoperative radiation delivery, cytotoxic agents, and hormonal treatment using luteinizing hormone-releasing hormone (LH-RH) agonists and/or antiandrogens.
Sources: RTOG-9601
Radical prostatectomy compared with other treatment options
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In 1993, a structured literature review of 144 papers was done in an attempt to compare the three primary treatment strategies for clinically localized prostate cancer:[30]
Sources: 30
Radical prostatectomy.
Definitive radiation therapy.
Observation (watchful waiting or active surveillance/active monitoring).
The authors concluded that poor reporting and selection factors within all series precluded a valid comparison of efficacy for the three management strategies.
In a literature review of case series of patients with palpable, clinically localized disease, the authors found that 10-year prostate−cancer-specific survival rates were best in radical prostatectomy series (about 93%), worst in radiation therapy series (about 75%), and intermediate with deferred treatment (about 85%).[31] Because it is highly unlikely that radiation therapy would worsen disease-specific survival, the most likely explanation is that selection factors affect choice of treatment. Such selection factors make comparisons of therapeutic strategies imprecise.[32]
Radical prostatectomy has been compared with watchful waiting or active surveillance/active monitoring in men with early-stage disease (i.e., clinical stages T1b, T1c, or T2) in randomized trials, with conflicting results. The difference in results may be the result of differences in how the men were diagnosed with prostate cancer.
Evidence (radical prostatectomy vs. watchful waiting or active surveillance/active monitoring):
In a randomized clinical trial performed in Sweden in the pre-PSA screening era, 695 men with prostate cancer were randomly assigned to radical prostatectomy versus watchful waiting. Only about 5% of the men in the trial had been diagnosed by PSA screening. Therefore, the men had more extensive local disease than is typically the case in men diagnosed with prostate cancer in the United States.[33-35]
In a randomized clinical trial performed in Sweden in the pre-PSA screening era, 695 men with prostate cancer were randomly assigned to radical prostatectomy versus watchful waiting. Only about 5% of the men in the trial had been diagnosed by PSA screening. Therefore, the men had more extensive local disease than is typically the case in men diagnosed with prostate cancer in the United States.[33-35]
The cumulative overall mortality at 18 years was 56.1% in the radical prostatectomy arm and 68.9% in the watchful waiting study arm (absolute difference, 12.7%; 95% confidence interval [CI], 5.1–20.3 percentage points; relative risk [RR]death, 0.71; 95% CI, 0.59–0.86).[35][Level of evidence A1]
Sources: 35 · Level of evidence A1
The cumulative incidence of prostate cancer deaths at 18 years was 17.7% versus 28.7% (absolute difference, 11.0%; 95% CI, 4.5–17.5 percentage points; RRdeath from prostate cancer, 0.56; 95% CI, 0.41–0.77).[35]
Sources: 35
In a post-hoc–subset analysis, the improvement in overall and prostate cancer-specific mortality associated with radical prostatectomy was restricted to men younger than 65 years.
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy or watchful waiting.[5,36,37][Level of evidence A1]
Sources: PIVOT-1 · 5 · 36 · 37 · Level of evidence A1
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy or watchful waiting.[5,36,37][Level of evidence A1]
About 50% of the men had nonpalpable, screen-detected disease.
After a median follow-up of 12.7 years (range up to about 19.5 years), the all-cause mortality was 61.3% in the prostatectomy arm versus 66.8% in the watchful-waiting study arm, with an absolute difference of 5.5 percentage points (95% CI, -1.5–12.4) that was not statistically significant (hazard ratio [HR], 0.84; 95% CI, 0.70–1.01). Prostate cancer-specific mortality was 7.4% versus 11.4%, and it also was not statistically significant (HR, 0.63; 95% CI, 0.3–1.02).
Although treatment for disease progression was given more frequently in the observation arm of the study, most of the treatment was for asymptomatic, local, or biochemical (PSA) progression.
As expected, urinary incontinence and erectile/sexual dysfunction was more common in the prostatectomy group during at least 10 years of follow-up. Absolute differences in patient-reported use of absorbent urinary pads was greater in the surgery group by more than 30 percentage points at all time points for at least 10 years. Disease- or treatment-related limitations in activities of daily living were worse with surgery than with observation through 2 years, but then were similar in both study arms.
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3-dimensional (3D) conformal radiation therapy (74 Gy in 37 fractions). The primary end point was prostate cancer–specific mortality.[19]
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3-dimensional (3D) conformal radiation therapy (74 Gy in 37 fractions). The primary end point was prostate cancer–specific mortality.[19]
With a median follow-up of 10 years, there were 17 deaths from prostate cancer, with no statistically significant differences among the three study arms (P = .48). The 10-year prostate cancer–specific survival rates were 98.8% in the active monitoring arm, 99.0% in the radical prostatectomy arm, and 99.6% in the radiation therapy arm.[19][Level of evidence A1]
Sources: 19 · Level of evidence A1
Likewise, all-cause mortality was nearly identical in all three study arms: 10.9 deaths in the active monitoring arm, 10.1 in the radical prostatectomy arm, and 10.3 in the radiation therapy arm per 1,000 person-years (P = .87).[19][Level of evidence A1]
Sources: 19 · Level of evidence A1
There were statistically significant differences in progression to metastatic disease among the treatment arms (33 of 545 men in the active monitoring arm; 13 of 553 men in the radical prostatectomy arm; 16 of 545 men in the radiation therapy arm) that began to emerge after 4 years, but these differences had not translated into any difference in mortality after 10 years of follow-up. Over the course of 10 years, 52% of the patients required active intervention.
As expected, there were substantial differences in patient-reported outcomes among the three management approaches.[38][Level of evidence A3] A substudy of patient-reported outcomes up to 6 years after randomization included the following results:
Sources: 38 · Level of evidence A3
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3-dimensional (3D) conformal radiation therapy (74 Gy in 37 fractions). The primary end point was prostate cancer–specific mortality.[19] › As expected, there were substantial differences in patient-reported outcomes among the three management approaches.[38][Level of evidence A3] A substudy of patient-reported outcomes up to 6 years after randomization included the following results:
Men in the radical prostatectomy study arm had substantial rates of urinary incontinence (e.g., using one or more absorbent pads qd was reported by 46% at 6 months and by 17% at year 6) with very little incontinence in the other two study arms.
Sexual function was also worse in the radical prostatectomy group (e.g., at 6 months, 12% of men reported erections firm enough for intercourse versus 22% in the radiation therapy arm and 52% in the active monitoring arm).
Bowel function, however, was worse in the radiation therapy arm (e.g., about 5% reported bloody stools at least half the time at 2 years and beyond vs. none in the radical prostatectomy and active-monitoring study arms).
Complications of radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Complications of radical prostatectomy include:
Morbidity and mortality associated with general anesthesia and a major surgical procedure.[39-41]
Sources: Morbidity and mortality · 39 · 41
Urinary incontinence and impotence.[42-49]
Sources: Urinary incontinence and impotence · 42 · 49
Penile shortening.[50-52]
Sources: Penile shortening · 50 · 52
Inguinal hernia.[53-57]
Sources: Inguinal hernia · 53 · 57
Fecal incontinence.[58]
Sources: Fecal incontinence · 58
Functional outcomes of radical prostatectomy with respect to sexual, urinary, bowel function, and health-related quality of life (QOL), appear to be similar whether the procedure is open retropubic, laparoscopic, or robot-assisted radical prostatectomy.[59]
Sources: 59
Morbidity and mortality associated with radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
An analysis of Medicare records on 101,604 radical prostatectomies performed from 1991 to 1994 showed the following results:[39]
Sources: 39
A 30-day operative mortality rate of 0.5%.
A rehospitalization rate of 4.5%.
A major complication rate of 28.6%.
Over the study period, these rates decreased by 30%, 8%, and 12%, respectively.[39]
Sources: 39
The following outcomes were associated with prostatectomies done at hospitals where fewer of the procedures were performed than those done at hospitals where more were performed:[40,41]
Higher rates of 30-day postoperative mortality.
Major acute surgical complications.
Longer hospital stays.
Higher rates of rehospitalization.
Operative morbidity and mortality rates increase with age. Comorbidity, especially underlying cardiovascular disease and a history of stroke, accounts for a portion of the age-related increase in 30-day mortality.
In a cohort of all men with prostate cancer who underwent radical prostatectomy from 1990 to 1999 in Ontario, 75-year-old men with no comorbidities had a predicted 30-day mortality of 0.74%. Thirty-day surgical complication rates also depended more on comorbidity than age (i.e., about 5% vs. 40% for men with 0 vs. ≥4 underlying comorbid conditions, respectively).[41]
Sources: 41
Urinary incontinence and impotence
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Urinary incontinence and impotence are complications that can result from radical prostatectomy and have been studied in multiple studies.
Evidence (urinary incontinence and impotence after radical prostatectomy):
A large case series of men undergoing the anatomic (nerve-sparing) technique of radical prostatectomy reported the following results:[43]
Sources: 43
A large case series of men undergoing the anatomic (nerve-sparing) technique of radical prostatectomy reported the following results:[43]
Approximately 6% of the men required the use of pads for urinary incontinence, but an unknown additional proportion of men had occasional urinary dribbling.
About 40% to 65% of the men who were sexually potent before surgery retained potency adequate for vaginal penetration and sexual intercourse. Preservation of potency with this technique is dependent on tumor stage and patient age, but the operation probably induces at least a partial deficit in nearly all patients.
A national survey of Medicare patients who underwent radical prostatectomy in 1988 to 1990 reported more morbidity than in the case series reported above.[44]
Sources: 44
A national survey of Medicare patients who underwent radical prostatectomy in 1988 to 1990 reported more morbidity than in the case series reported above.[44]
More than 30% of the men reported the need for pads or clamps for urinary wetness, and 63% of all patients reported a current problem with wetness.
About 60% of the men reported having no erections since surgery; about 90% of the men had no erections sufficient for intercourse during the month before the survey.
About 28% of the patients reported follow-up treatment of cancer with radiation therapy and/or hormonal therapy within 4 years after their prostatectomy.
A population-based longitudinal cohort study (Prostate Cancer Outcomes Study) included 901 men aged 55 to 74 years who had recently undergone radical prostatectomy for prostate cancer.[45]
Sources: Prostate Cancer Outcomes Study · 45
A population-based longitudinal cohort study (Prostate Cancer Outcomes Study) included 901 men aged 55 to 74 years who had recently undergone radical prostatectomy for prostate cancer.[45]
15.4% of the men had either frequent urinary incontinence or no urinary control at 5 years after surgery.
20.4% of those studied wore pads to stay dry.
79.3% of men reported an inability to have an erection sufficient for intercourse.
A cross-sectional survey of patients with prostate cancer who were treated with radical prostatectomy, radiation therapy, or watchful waiting and active surveillance in a managed care setting showed substantial sexual and urinary dysfunction in the prostatectomy group.[46]
Sources: 46
A cross-sectional survey of patients with prostate cancer who were treated with radical prostatectomy, radiation therapy, or watchful waiting and active surveillance in a managed care setting showed substantial sexual and urinary dysfunction in the prostatectomy group.[46]
Results reported by the patients were consistent with those from the national Medicare survey.
In addition, although statistical power was limited, differences in sexual and urinary dysfunction between men who had undergone either nerve-sparing or standard radical prostatectomy were not statistically significant. This issue requires more study.
Case series of 93, 459, and 89 men who had undergone radical prostatectomy by experienced surgeons showed rates of impotence as high as those in the national Medicare survey when men were carefully questioned about sexual potency, although the men in these case series were on average younger than those in the Medicare survey.[47-49] One of the case series used the same questionnaire as that used in the Medicare survey.[47] The urinary incontinence rate in that series was also similar to that in the Medicare survey.
Differences are often reported between population-based surveys and case series from individual centers. Reasons for these differences could include:
Age differences among the populations.
Surgical expertise at the major reporting centers.
Patient selection factors.
Publication bias of favorable series.
Different methods of collecting information from patients.
Penile shortening
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Case series of men who have undergone radical prostatectomy have shown shortening of penile length (by an average of 1–2 cm).[50-52] The functional consequence of the shortening is not well studied, but it is noticeable to some men.
In a registry of men with rising PSA after initial treatment of clinically localized prostate cancer, 19 of 510 men (3.7%) who had undergone radical prostatectomy complained of reduced penile size.[60] However, the data were based upon physician reporting of patients' complaints rather than direct patient questioning or before-and-after measurement of penile length. Also, the study sample was restricted to patients with known or suspected tumor recurrence, making generalization difficult.
Sources: 60
Recovery of penile length to preoperative measurements within 1 to 2 years has been reported in some, but not all, case series in which men were followed longitudinally.[61]
Sources: 61
Inguinal hernia
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Inguinal hernia has been reported as a complication of radical prostatectomy.
Evidence (inguinal hernia after radical prostatectomy):
Retrospective cohort studies and case series have shown an increased incidence of inguinal hernia, ranging from 7% to 21%, in men undergoing radical prostatectomy, with rates peaking within 2 years of surgery.[53-57]
Observational studies suggest that the rates are higher than in comparable men who have undergone prostate biopsy alone, transurethral resections, and simple open prostatectomy for benign disease;[53,54] or in men with prostate cancer who have undergone pelvic lymph node dissection alone or radiation therapy.[53,55,56]
Although the observations of increased rates of inguinal hernia after radical prostatectomy are consistent, it is conceivable that men with prostate cancer who are being followed carefully by urologists could have higher detection rates of hernia because of frequent examinations or diagnostic imaging (i.e., detection bias). Men should be made aware of this potential complication of prostatectomy.
Fecal incontinence
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radical prostatectomy may cause fecal incontinence, and the incidence may vary with surgical method.[58]
Sources: 58
Evidence (fecal incontinence after radical prostatectomy):
In a national survey sample of 907 men who had undergone radical prostatectomy at least 1 year before the survey, 32% of the men who had undergone perineal (nerve-sparing) radical prostatectomy and 17% of the men who had undergone a retropubic radical prostatectomy reported accidents of fecal leakage. Ten percent of the respondents reported moderate amounts of fecal leakage, and 4% of the respondents reported large amounts of fecal leakage. Fewer than 15% of men with fecal incontinence had reported it to a physician or health care provider.[58]
Sources: 58
Radiation Therapy and Radiopharmaceutical Therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
External-beam radiation therapy (EBRT)
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Candidates for definitive radiation therapy must have a confirmed pathological diagnosis of cancer that is clinically confined to the prostate and/or surrounding tissues (stage I, stage II, and stage III). Staging laparotomy and lymph node dissection are not required.
Radiation therapy may be a good option for patients who are considered poor medical candidates for radical prostatectomy. These patients can be treated with an acceptably low complication rate if care is given to the delivery technique.[62]
Sources: 62
Long-term results with radiation therapy are dependent on stage and are associated with dosimetry of the radiation.
Evidence (EBRT):
A retrospective review of 999 patients treated with megavoltage radiation therapy showed that cause-specific survival rates at 10 years varied substantially by T stage: T1 (79%), T2 (66%), T3 (55%), and T4 (22%).[63] An initial serum PSA level higher than 15 ng/mL is a predictor of probable failure with conventional radiation therapy.[64]
Several randomized studies have demonstrated an improvement in freedom from biochemical (PSA-based) recurrence with higher doses of radiation therapy (74–79 Gy) as compared with lower doses (64–70 Gy).[65-69][Level of evidence B1] None of the studies demonstrated a cause-specific survival benefit to higher doses.
Sources: 65 · 69 · Level of evidence B1
Several randomized studies have demonstrated an improvement in freedom from biochemical (PSA-based) recurrence with higher doses of radiation therapy (74–79 Gy) as compared with lower doses (64–70 Gy).[65-69][Level of evidence B1] None of the studies demonstrated a cause-specific survival benefit to higher doses.
The MRC-RT01 study (NCT00003290) enrolled 843 men with stage T1b through T3a, N0, M0 prostate cancer. Patients were randomly assigned to receive 64 Gy in 32 fractions versus 74 Gy in 37 fractions by conformal delivery.[68] Men in both study groups received neoadjuvant LH-RH agonist injections every 4 weeks for 3 to 6 months before the start of radiation therapy and throughout the radiation course. The study was powered to detect differences in both biochemical progression-free survival (PFS) and a 15% difference in overall survival (OS).
After a median follow-up of 10 years, despite a statistically significant improvement in biochemical PFS with the higher dose of radiation, the 10-year OS rate was the same in both groups: 71% (HR, 0.99; 95% CI, 0.77–1.28; P = .96). Likewise, there were no differences in prostate—cancer-specific survival.
Likewise, in the RTOG-0126 trial (NCT00033631), 1,532 men with stage cT1b to T2b (Gleason score 2 to 6 and PSA 10 to <20 ng/mL or Gleason score 7 and PSA <15 ng/mL) prostate cancer were randomly assigned to receive 79.2 Gy in 44 fractions compared with 70.2 Gy in 39 fractions (using 3D conformal or intensity-modulated radiation therapy [IMRT]).[69] With a median follow-up of 8.4 years (maximum, 13.0 years), 8-year OS rates were 76% and 75% (HR, 1.00; 95% CI, 0.83–1.20; P = .98). However, the high-dose radiation was associated with increased late-grade 2 or greater gastrointestinal and genitourinary toxicities (21% and 12% with 79.2 Gy and 15% and 7% with 70.2 Gy).
For more information, see the Radical prostatectomy compared with other treatment options section.
Sources: Radical prostatectomy compared with other treatment options
Prophylactic radiation therapy to clinically or pathologically uninvolved pelvic lymph nodes does not appear to improve OS or prostate cancer-specific survival as was seen in the RTOG-7706 trial, for example.[70][Level of evidence A1]
Sources: 70 · Level of evidence A1
Conventional versus hypofractionated EBRT
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The more convenient schedules of hypofractionated radiation therapy (using fewer fractions at higher doses per fraction) appear to yield similar outcomes to conventional schedules of radiation, at least with respect to the intermediate outcomes of DFS and failure-free survival (low levels of evidence not known to translate into health outcomes), and early data on OS rates. However, hypofractionated radiation may incur more toxicity than standard doses, depending on the schedules used.[71]
Sources: 71
Evidence (conventional vs. hypofractionated EBRT):
In a small randomized trial, primarily from one treatment center, conventional hypofractionation was not found to be superior to conventional fractionation.[72] In the trial, 303 assessable men were randomly assigned to receive IMRT for a total of 76 Gy in 38 fractions at 2.0 Gy per fraction (conventional IMRT [CIMRT]) versus IMRT for a total of 70.2 Gy in 26 fractions at 2.7 per fraction (hypofractionated IMRT [HIMRT]).
Sources: 72
In a small randomized trial, primarily from one treatment center, conventional hypofractionation was not found to be superior to conventional fractionation.[72] In the trial, 303 assessable men were randomly assigned to receive IMRT for a total of 76 Gy in 38 fractions at 2.0 Gy per fraction (conventional IMRT [CIMRT]) versus IMRT for a total of 70.2 Gy in 26 fractions at 2.7 per fraction (hypofractionated IMRT [HIMRT]).
The primary end point was biochemical or clinical disease failure (BCDF). The 5-year BCDF rates in the two arms were 21.4% for the CIMRT arm (95% CI, 14.8%–28.7%) and 23.3% for the HIMRT arm (95% CI, 16.4%–31.0%; P = .75).
Likewise, there were no statistically significant differences in the secondary end points of overall mortality, prostate–cancer-specific mortality, prostate local failure, or distant failure, despite low mortality rates, and the trial was underpowered for mortality end points.[72][Level of evidence B1]
Sources: 72 · Level of evidence B1
The much larger, multicenter CHHiP trial (NCT00392535) evaluated conventional or hypofractionated high-dose intensity-modulated radiotherapy in 3,216 men with prostate cancer. The men had stages T1b–T3a, N0, M0 cancer and an estimated risk of seminal vesicle involvement of less than 30% and were randomly assigned in a 1:1:1 ratio to receive either 74 Gy in 37 fractions (the conventional-fraction arm), 60 Gy in 20 fractions, or 57 Gy in 19 fractions.[73,74] The trial was designed as a noninferiority study.
The much larger, multicenter CHHiP trial (NCT00392535) evaluated conventional or hypofractionated high-dose intensity-modulated radiotherapy in 3,216 men with prostate cancer. The men had stages T1b–T3a, N0, M0 cancer and an estimated risk of seminal vesicle involvement of less than 30% and were randomly assigned in a 1:1:1 ratio to receive either 74 Gy in 37 fractions (the conventional-fraction arm), 60 Gy in 20 fractions, or 57 Gy in 19 fractions.[73,74] The trial was designed as a noninferiority study.
The primary end point of biochemical or clinical treatment failure was reported after a median follow-up of 62.4 months. The 5-year failure-free survival rates were 88.3% (conventional, 74 Gy group), 90.6% (60 Gy group), and 85.9% (57 Gy group). The 60 Gy hypofractionated group fulfilled noninferiority criteria compared with conventional 74 Gy fractionation, but the 57 Gy group did not.[74][Level of evidence B1]
Sources: 74 · Level of evidence B1
Overall mortality rates were very similar in the three groups: 9%, 7%, and 8%.[74][Level of evidence A1]
Sources: 74 · Level of evidence A1
A QOL substudy was conducted with 2,100 participants and showed nearly identical patient-reported outcomes in each of the three arms at 2 years after study entry (median follow-up, 50 months).[73][Level of evidence A3]
Sources: 73 · Level of evidence A3
The primary patient-reported outcome was bowel bother. Frequency of moderate bother was 5%, 6%, and 5% in the three study groups. Severe bother was reported in less than 1% of men in each study group.
Likewise, there were no differences in any of the secondary outcomes, which included overall QOL, overall urinary bother, or overall sexual bother.
The multicenter, randomized, phase III HYPRO trial (ISRCTN85138529) enrolled 820 men with intermediate- or high-risk prostate cancer (stages T1b–T4, NX–0, MX–0). The men were randomly assigned to receive either conventional radiation therapy (78 Gy in 39 fractions over 8 weeks) or hypofractionated radiation therapy (64.6 Gy in 19 fractions over 6.5 weeks) in a noninferiority design for hypofractionation.[75,76] Median follow-up was 60 months.
The multicenter, randomized, phase III HYPRO trial (ISRCTN85138529) enrolled 820 men with intermediate- or high-risk prostate cancer (stages T1b–T4, NX–0, MX–0). The men were randomly assigned to receive either conventional radiation therapy (78 Gy in 39 fractions over 8 weeks) or hypofractionated radiation therapy (64.6 Gy in 19 fractions over 6.5 weeks) in a noninferiority design for hypofractionation.[75,76] Median follow-up was 60 months.
The primary end point, 5-year relapse-free survival, was similar in the two study arms: 80.5% (95% CI, 75.7%–84.4%) with hypofractionation versus 77.1% (95% CI, 71.9%–81.5%), with conventional fractionation (HR, 0.86; 95% CI, 0.63–1.16; P = .36).[76][Level of evidence B1] The overall 5-year survival rate in the two arms was also similar: 86.2% (95% CI, 82.3%–89.4%) with hypofractionation versus 85.9% (95% CI, 81.8%–89.2%) with conventional fractionation (HR, 1.02; 95% CI, 0.71–1.46; P = .92).[76][Level of evidence A1]
Sources: 76 · Level of evidence B1 · 76 · Level of evidence A1
With respect to toxicity (key end points of genitourinary [GU] or gastrointestinal [GI] grade 2 or higher toxicities at 3 years), noninferiority for hypofractionated radiation therapy could not be established after a median follow-up of 5 years: cumulative GU toxicity of 41.3% with hypofractionated radiation therapy versus 39% with conventional radiation therapy doses (HR, 1.16; 90% CI, 0.98–1.38); GI toxicity of 21.9% versus 17.7% (HR, 1.19; 90% CI, 0.93–1.52).
Cumulative GU grade 3 or higher toxicity was more common in the hypofractionation group: 19.0% versus 12.9% (P = .02).
Stool frequency (≥6 qd) was higher in the hypofractionation group: 7% versus 3% (P = .034).
In a substudy of 322 men who had a baseline assessment and at least one follow-up assessment, and either no or short-term androgen therapy, erectile dysfunction was similar between the two study arms during 3 years of follow-up.[77]
Sources: 77
The RTOG reported a noninferiority trial of 1,115 men with low-risk prostate cancer (T1b–T2c) who were randomly assigned to receive hypofractionated radiation therapy (70 Gy in 28 fractions over 5.6 weeks) versus conventional radiation therapy doses (73.8 Gy in 41 fractions over 8.2 weeks).[78]
Sources: 78
The RTOG reported a noninferiority trial of 1,115 men with low-risk prostate cancer (T1b–T2c) who were randomly assigned to receive hypofractionated radiation therapy (70 Gy in 28 fractions over 5.6 weeks) versus conventional radiation therapy doses (73.8 Gy in 41 fractions over 8.2 weeks).[78]
After a median follow-up of 5.8 years, the hypofractionated radiation therapy arm met the prospective noninferiority criterion with respect to DFS: 86.3% with hypofractionated radiation therapy versus 85.3% with conventional radiation therapy doses (consistent with HR, <1.52; P < .001 for the hypothesis of noninferiority).[78][Level of evidence B1]
Sources: 78 · Level of evidence B1
There were 49 deaths in the hypofractionated radiation therapy arm and 51 deaths in the conventional radiation therapy doses arm (HR for OS, 0.95; conventional radiation therapy doses vs. hypofractionated radiation therapy; 95% CI, 0.64–1.41).
However, late GI grade 2 or higher toxicity was worse in the hypofractionated radiation therapy arm: 22.4% versus 14.0% (P = .002); there was also a trend toward worse late GU grade 2 or higher toxicity: 29.7% versus 22.8% (P = .06).
In a multicenter trial (NCT00304759), 1,206 men with intermediate-risk prostate cancer (T1–2a Gleason score ≤6, PSA 10.1–20 ng/mL; T2b–2c Gleason ≤6, PSA ≤20 ng/mL; or T1–2 Gleason = 7, PSA ≤20 ng/mL) were randomly assigned in a noninferiority trial design to receive conventional radiation therapy (78 Gy in 39 fractions) versus hypofractionated radiation therapy (60 Gy over 20 fractions).[79]
Sources: NCT00304759 · 79
In a multicenter trial (NCT00304759), 1,206 men with intermediate-risk prostate cancer (T1–2a Gleason score ≤6, PSA 10.1–20 ng/mL; T2b–2c Gleason ≤6, PSA ≤20 ng/mL; or T1–2 Gleason = 7, PSA ≤20 ng/mL) were randomly assigned in a noninferiority trial design to receive conventional radiation therapy (78 Gy in 39 fractions) versus hypofractionated radiation therapy (60 Gy over 20 fractions).[79]
After a median follow-up of 6 years (maximum 10 years), the primary end point of biochemical clinical failure (87%, PSA failure) was nearly identical with each radiation therapy schedule (85% in both arms; [DFS, 95% CI, 82%–88%]; HR, 0.96; 90% CI, 0.77–1.20).[79][Level of evidence B1]
Sources: 79 · Level of evidence B1
The trial was severely underpowered to detect any differences in overall or prostate-specific mortality. Only 12 deaths in the conventional radiation therapy arm and 10 deaths in the hypofractionated radiation therapy arm were from prostate cancer. Only 14% of all deaths were attributed to prostate cancer.
Short- and long-term genitourinary and gastrointestinal toxicities were similar in both study groups.
Brachytherapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Patients are often offered brachytherapy because of the following favorable characteristics:
Low Gleason score.
Low PSA level.
Stage T1 to T2 tumors.
More information and further study are required to better define the effects of modern interstitial brachytherapy on disease control and QOL and to determine the contribution of favorable patient selection to outcomes.[80][Level of evidence C3]
Sources: 80 · Level of evidence C3
Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Radiopharmaceutical therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Alpha emitter radiation
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radium Ra 223 (223Ra) emits alpha particles (i.e., two protons and two neutrons bound together, identical to a helium nucleus) with a half-life of 11.4 days. It is administered intravenously and selectively taken up by newly formed bone stroma. The high-energy alpha particles have a short range of less than 100 mcM. 223Ra improved OS in patients with prostate cancer metastatic to bone. In a double-blind, randomized, controlled trial, 921 men with symptomatic castration-resistant prostate cancer, two or more metastases, and no known visceral metastases were randomly assigned in a 2:1 ratio to 223Ra versus placebo. 223Ra statistically significantly improved OS (median 14.9 months vs. 11.3 months), rate of symptomatic skeletal events (33% vs. 38%), and spinal cord compression (4% vs. 7%).[81,82][Level of evidence A1] With administration at a dose of 50kBq per kg body weight every 4 weeks for six injections, the side effects were similar to those of a placebo.
Sources: 81 · 82 · Level of evidence A1
Complications of radiation therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Definitive EBRT can result in acute cystitis, proctitis, and enteritis.[20,42,49,83-85] These conditions are generally reversible but may be chronic and rarely require surgical intervention.[85]
A cross-sectional survey of patients with prostate cancer who had been treated in a managed care setting by radical prostatectomy, radiation therapy, or watchful waiting and active surveillance showed substantial sexual and urinary dysfunction in the radiation therapy group.[46]
Sources: 46
Reducing complications
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Potency, in most cases, is preserved with radiation therapy in the short term but appears to diminish over time.[85] Sildenafil citrate may be effective in the management of sexual dysfunction after radiation therapy in some men.
Sources: 85
Evidence (reducing complications):
In a completed, randomized, placebo-controlled, crossover design study (RTOG-0215 [NCT00057759]) of 60 men who had undergone radiation therapy for clinically localized prostate cancer, and who reported erectile dysfunction that began after their radiation therapy, 55% reported successful intercourse after sildenafil versus 18% after placebo (P < .001).[89][Level of evidence A3]
Sources: RTOG-0215 · 89 · Level of evidence A3
A randomized trial (RTOG-0831 [NCT00931528]) of 121 men with intact erectile function compared daily preventive tadalafil (5 mg PO qd) with placebo for 24 weeks beginning at the start of either EBRT or brachytherapy.[90][Level of evidence A3]
Sources: RTOG-0831 · 90 · Level of evidence A3
A randomized trial (RTOG-0831 [NCT00931528]) of 121 men with intact erectile function compared daily preventive tadalafil (5 mg PO qd) with placebo for 24 weeks beginning at the start of either EBRT or brachytherapy.[90][Level of evidence A3]
There were no statistically significant differences in spontaneous erectile function (the primary end point) or any other measures of sexual function.
Morbidity may be reduced with the employment of sophisticated radiation therapy techniques—such as the use of linear accelerators—and careful simulation and treatment planning.[91,92]
Evidence (3D conformal vs. conventional radiation therapy):
The side effects of similar doses of 3D conformal radiation therapy and conventional radiation therapy (total dose, 60–64 Gy) have been compared in a randomized nonblinded study.[92][Level of evidence A3]
Sources: 92 · Level of evidence A3
The side effects of similar doses of 3D conformal radiation therapy and conventional radiation therapy (total dose, 60–64 Gy) have been compared in a randomized nonblinded study.[92][Level of evidence A3]
No differences were observed in acute morbidity, and late side effects serious enough to require hospitalization were infrequent with both techniques; however, the cumulative incidence of mild or greater proctitis was lower in the conformal radiation arm than in the standard therapy arm (37% vs. 56%; P = .004). Urinary symptoms were similar in the two treatment groups, as were local tumor control and OS rates at 5 years of follow-up.
Radiation therapy can be delivered after an extraperitoneal lymph node dissection without an increase in complications if careful attention is paid to radiation technique. The treatment field should not include the area that contained the dissected pelvic nodes. Previous TURP is associated with an increased risk of stricture above that seen with radiation therapy alone, but, if radiation therapy is delayed 4 to 6 weeks after the TURP, the risk of stricture is lower.[93-95] Pretreatment TURP to relieve obstructive symptoms has been associated with tumor dissemination; however, multivariable analysis in pathologically staged cases indicates that this may be due to a worse underlying prognosis of the cases that require TURP rather than the result of the procedure itself.[96]
Comparison of complications from radiation therapy and from radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In general, radical prostatectomy is associated with a higher rate of urinary incontinence and early sexual impotence but a lower rate of stool incontinence and rectal injury. However, over time, the differences in sexual impotence diminish because the risk rises with time since radiation. Many side effects of definitive local therapy for prostate cancer persist well beyond a decade after therapy, and urinary problems in addition to sexual impotence may worsen with age.[97]
Sources: 97
Evidence (complications of radical prostatectomy vs. radiation therapy):
A population-based survey of Medicare recipients who had received radiation therapy as primary treatment for prostate cancer (similar in design to the survey of Medicare patients who underwent radical prostatectomy,[44] described above) has been reported, showing substantial differences in posttreatment morbidity profiles between surgery and radiation therapy.[98]
A population-based survey of Medicare recipients who had received radiation therapy as primary treatment for prostate cancer (similar in design to the survey of Medicare patients who underwent radical prostatectomy,[44] described above) has been reported, showing substantial differences in posttreatment morbidity profiles between surgery and radiation therapy.[98]
Although the men who had undergone radiation therapy were older at the time of initial therapy, they were less likely to report the need for pads or clamps to control urinary wetness (7% vs. >30%).
A larger proportion of patients treated with radiation therapy before surgery reported the ability to have an erection sufficient for intercourse in the month before the survey (men <70 years, 33% who received radiation therapy vs. 11% who underwent surgery alone; men ≥70 years, 27% who received radiation therapy vs. 12% who underwent surgery alone).
Men receiving radiation therapy, however, were more likely to report problems with bowel function, especially frequent bowel movements (10% vs. 3%).
As in the results of the surgical patient survey, about 24% of patients who received radiation reported additional subsequent treatment for known or suspected cancer persistence or recurrence within 3 years of primary therapy.
A prospective, community-based cohort study of men aged 55 to 74 years treated with radical prostatectomy (n = 1,156) or EBRT (n = 435) attempted to compare the acute and chronic complications of the two treatment strategies after adjusting for baseline differences in patient characteristics and underlying health.[99]
Sources: 99
A prospective, community-based cohort study of men aged 55 to 74 years treated with radical prostatectomy (n = 1,156) or EBRT (n = 435) attempted to compare the acute and chronic complications of the two treatment strategies after adjusting for baseline differences in patient characteristics and underlying health.[99]
Regarding acute treatment-related morbidity, radical prostatectomy was associated with higher rates of cardiopulmonary complications (5.5% vs. 1.9%) and the need for treatment of urinary strictures (17.4% vs. 7.2%). Radiation therapy was associated with more acute rectal proctitis (18.7% vs. 1.6%).
With regard to chronic treatment-related morbidity, radical prostatectomy was associated with more urinary incontinence (9.6% vs. 3.5%) and impotence (80% vs. 62%). Radiation therapy was associated with slightly greater declines in bowel function.
Hormonal Therapy and Its Complications
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Several different hormonal approaches are used in the management of various stages of prostate cancer.
These approaches include:
Abiraterone acetate (added to androgen deprivation therapy [ADT]).
Sources: Abiraterone acetate
Bilateral orchiectomy.
Sources: Bilateral orchiectomy
Estrogen therapy.
Sources: Estrogen therapy
Luteinizing hormone-releasing hormone (LH-RH) agonist therapy.
Sources: Luteinizing hormone-releasing hormone (LH-RH) agonist therapy
Antiandrogen therapy.
Sources: Antiandrogen therapy
ADT.
Sources: ADT
Antiadrenal therapy.
Sources: Antiadrenal therapy
Antiadrenal therapy.
Ketoconazole.
Aminoglutethimide.
Abiraterone acetate
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Abiraterone acetate has been shown to improve OS when added to ADT in men with advanced prostate cancer who have castration-sensitive disease. Abiraterone acetate is generally well-tolerated; however, it is associated with an increase in the mineralocorticoid effects of grade 3 or 4 hypertension and hypokalemia compared with ADT alone.[100] It may also be associated with a small increase in respiratory disorders.[101]
Bilateral orchiectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Benefits of bilateral orchiectomy include:[42]
Sources: 42
Ease of the procedure.
Compliance.
Immediacy in lowering testosterone levels.
Low cost relative to the other forms of ADT.
Psychological effects.
Loss of libido.
Less reversible impotence.
Hot flashes.
Osteoporosis.[102]
Sources: 102
Bilateral orchiectomy has also been associated with an elevated risk of coronary heart disease and myocardial infarction.[103-106]
For more information, see Hot Flashes and Night Sweats.
Sources: Hot Flashes and Night Sweats
Estrogen therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Estrogens at a dose of 3 mg qd of diethylstilbestrol (DES) will achieve castrate levels of testosterone. Like orchiectomy, estrogens may cause loss of libido and impotence. Estrogens also cause gynecomastia, and prophylactic low-dose radiation therapy to the breasts is given to prevent this complication.
DES is no longer manufactured or marketed in the United States and is seldom used today because of the risk of serious side effects, including myocardial infarction, cerebrovascular accidents, and pulmonary embolism.
Luteinizing hormone-releasing hormone (LH-RH) agonist therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
LH-RH agonists, such as leuprolide, goserelin, and buserelin, lower testosterone to castrate levels. Like orchiectomy and estrogens, LH-RH agonists cause impotence, hot flashes, and loss of libido. Tumor flare reactions may occur transiently but can be prevented by antiandrogens or short-term estrogens at a low dose for several weeks.
There is some evidence that LH-RH agonists are associated with increased risk of cardiovascular morbidity or mortality, although the results are conflicting.[103-107]
Evidence (LH-RH agonists and cardiovascular disease):
In a population-based study within the Department of Veterans Affairs' system, LH-RH agonists were associated with an increased risk of diabetes as well as cardiovascular disease, including coronary heart disease, myocardial infarction, sudden death, and stroke.[103-105]
A systematic evidence review and meta-analysis of eight trials (4,141 patients) of men with nonmetastatic prostate cancer who were randomly assigned to receive or not to receive LH-RH agonists found no difference in cardiovascular death rates (11.0% vs. 11.2%; RRdeath, 0.93; 95% CI, 0.79–1.10; P = .41).[108] Median follow-up in those studies was 7.6 to 13.2 years. No excess risk of LH-RH agonists was found regardless of treatment duration or patient age (median age of <70 years or ≥70 years).
Sources: 108
Antiandrogen therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Antiandrogen agents used in the treatment of prostate cancer include flutamide and bicalutamide. A systematic evidence review compared nonsteroidal antiandrogen monotherapy with surgical or medical castration from 11 randomized trials in 3,060 men with locally advanced, metastatic, or recurrent disease after local therapy.[109] Use of nonsteroidal antiandrogens as monotherapy decreased OS and increased the rate of clinical progression and treatment failure.[109][Level of evidence A1]
Sources: 109 · 109 · Level of evidence A1
The pure antiandrogen, flutamide, may cause diarrhea, breast tenderness, and nausea. Case reports show fatal and nonfatal liver toxic effects.[110] For more information, see Gastrointestinal Complications.
Sources: 110 · Gastrointestinal Complications
Bicalutamide may cause nausea, breast tenderness, hot flashes, loss of libido, and impotence.[111] For more information, see Nausea and Vomiting Related to Cancer Treatment and Hot Flashes and Night Sweats.
Sources: 111 · Nausea and Vomiting Related to Cancer Treatment · Hot Flashes and Night Sweats
The steroidal antiandrogen, megestrol acetate, suppresses androgen production incompletely and is generally not used as initial therapy.
Additional studies that evaluate the effects of various hormone therapies on QOL are required.[112]
Sources: 112
ADT
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
A national Medicare survey of men who had undergone radical prostatectomy for prostate cancer and either had or had not undergone androgen depletion (either medically or surgically induced) showed a decrease with androgen depletion in all seven health-related QOL measures, including:[113][Level of evidence C1]
Sources: 113 · Level of evidence C1
Impact of cancer and treatment.
Concern regarding body image.
Mental health.
General health.
Activity.
Worries about cancer and dying.
Energy.
ADT can cause osteoporosis and bone fractures. In a population-based sample of 50,613 Medicare patients aged 66 years or older followed for a median of 5.1 years, men who had been treated with either a gonadotropin-releasing hormone (GnRH) or orchiectomy had a 19.4% bone fracture rate compared with 12.6% in men who had not received hormone deprivation therapy. The effect was similar in men whether or not they had metastatic bone disease.[114]
Sources: 114
The use of ADT may be associated with complaints of penile shortening, although the data are very limited.[60] In a registry study of men with rising PSA after initial treatment of clinically localized prostate cancer treated with radiation therapy plus ADT, 6 of 225 men (2.7%) complained of reduced penile size. Of the 213 men treated with radiation therapy but no ADT, none complained of changes in penile size. However, the data were based upon physician reporting of patients' complaints rather than direct patient questioning or before-and-after measurement of penile length. Also, the study sample was restricted to patients with known or suspected tumor recurrence, making generalization difficult.
Sources: 60
Placebo-controlled, randomized trials have shown that treatment of bone loss with bisphosphonates decreases the risk of bone fracture in men receiving ADT for prostate cancer (RR, 0.80 in a meta-analysis of 15 trials; 95% CI, 0.69–0.94). In the meta-analysis, zoledronate appeared to have the largest effect.[115]
Sources: 115
The use of ADT has also been associated with an increased risk of colorectal cancer.
Evidence (increased risk of colorectal cancer):
Using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, investigators assessed the risk of subsequent colorectal cancer in 107,859 men aged 67 years and older after an initial diagnosis of prostate cancer.[116]
Sources: 116
Using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, investigators assessed the risk of subsequent colorectal cancer in 107,859 men aged 67 years and older after an initial diagnosis of prostate cancer.[116]
The rates of colorectal cancer per 1,000 person-years were 6.3 (95% CI, 5.3–7.5) in men who had orchiectomy, 4.4 (95% CI, 4.0–4.9) in men treated with GnRH agonists, and 3.7 (95% CI, 3.5–3.9) in men who had no androgen deprivation.
In men treated with GnRH agonists, the risk increased with increasing duration of treatment (P for trend = .01).
Antiadrenal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Antiadrenal agents used in the treatment of prostate cancer include ketoconazole and aminoglutethimide. Long-term use of ketoconazole can result in impotence, pruritus, nail changes, and adrenal insufficiency. Aminoglutethimide commonly causes sedation and skin rashes. For more information, see Pruritus.
Sources: Pruritus
Cryosurgery
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Cryosurgery, or cryotherapy, is under evaluation for the treatment of localized prostate cancer. It is a surgical technique that involves destruction of prostate cancer cells by intermittent freezing of the prostate with cryoprobes, followed by thawing.[117][Level of evidence C1]; [118,119][Level of evidence C3] There is limited evidence regarding its efficacy and safety compared with standard prostatectomy and radiation therapy, and the technique is evolving in an attempt to reduce local toxicity and normal tissue damage. The quality of evidence on efficacy is low, currently limited to case series of relatively small size, short follow-up, and surrogate outcomes of efficacy.[120]
Sources: 117 · Level of evidence C1 · 118 · 119 · Level of evidence C3 · 120
Serious toxic effects associated with cryosurgery include bladder outlet injury, urinary incontinence, sexual impotence, and rectal injury. Impotence is common, ranging from about 47% to 100%.
The frequency of other side effects and the probability of cancer control at 5 years of follow-up have varied among reporting centers, and series are small compared with surgery and radiation therapy.[118,119] Other major complications include urethral sloughing, urinary fistula or stricture, and bladder neck obstruction.[120]
Proton-Beam Therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
There is interest in the use of proton-beam therapy for the treatment of prostate cancer. Although the dose distribution of this form of charged-particle radiation could theoretically improve the therapeutic ratio of prostate radiation, allowing for an increase in dose to the tumor without a substantial increase in side effects, no randomized controlled trials have been reported that compare its efficacy and toxicity with those of other forms of radiation therapy.
Photodynamic Therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Vascular-targeted photodynamic therapy using a photosensitizing agent has been tested in men with low-risk prostate cancer.[121]
Sources: 121
Neoadjuvant Hormonal Therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Bicalutamide
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Bicalutamide has not been shown to improve OS in patients with localized or locally advanced prostate cancer.
Evidence (bicalutamide):
The Early Prostate Cancer program is a large, randomized, placebo-controlled, international trial that compared bicalutamide (150 mg PO qd) plus standard care (radical prostatectomy, radiation therapy, or watchful waiting, depending on local custom) with standard care alone for men with nonmetastatic localized or locally advanced prostate cancer (T1–2, N0, and NX; T3–4, any N; or any T, N+). Less than 2% of the 8,113 men had known nodal disease.[122][Level of evidence A1]
Sources: 122 · Level of evidence A1
The Early Prostate Cancer program is a large, randomized, placebo-controlled, international trial that compared bicalutamide (150 mg PO qd) plus standard care (radical prostatectomy, radiation therapy, or watchful waiting, depending on local custom) with standard care alone for men with nonmetastatic localized or locally advanced prostate cancer (T1–2, N0, and NX; T3–4, any N; or any T, N+). Less than 2% of the 8,113 men had known nodal disease.[122][Level of evidence A1]
At a median follow-up of 7.4 years, there was no difference in OS between the bicalutamide and placebo groups (about 76% in both arms [HR, 0.99; CI, 95%, 0.91–1.09; P = .89]).
Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Treatment of Stage I Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Overview
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Stage I prostate cancer is defined by the American Joint Committee on Cancer's TNM (tumor, node, metastasis) classification system:[1]
Sources: 1
cT1a–c, N0, M0, prostate-specific antigen (PSA) <10 ng/mL, Gleason ≤6.
cT2a, N0, M0, PSA <10 ng/mL, Gleason ≤6.
pT2, N0, M0, PSA <10 ng/mL, Gleason ≤6.
The frequency of clinically silent, nonmetastatic prostate cancer that can be found at autopsy greatly increases with age and may be as high as 50% to 60% in men aged 90 years and older. Undoubtedly, the incidental discovery of these occult cancers at prostatic surgery performed for other reasons accounts for the similar survival of men with stage I prostate cancer, compared with the normal male population, adjusted for age.
Many stage I cancers are well differentiated and only focally involve the gland (T1a, N0, M0); most require no treatment other than careful follow-up.[2]
Sources: 2
In younger patients (aged 50–60 years) whose expected survival is long, treatment should be considered.[3] Radical prostatectomy, external-beam radiation therapy (EBRT), interstitial implantation of radioisotopes, and watchful waiting and active surveillance/active monitoring yield apparently similar survival rates in noncontrolled, selected series. The decision to treat should be made in the context of the patient’s age, associated medical illnesses, and personal desires.[3]
Treatment Options for Stage I Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for patients with stage I prostate cancer include:
Sources: stage I prostate cancer
Watchful waiting or active surveillance/active monitoring.
Sources: Watchful waiting or active surveillance/active monitoring
Radical prostatectomy.
Sources: Radical prostatectomy
External-beam radiation therapy (EBRT).
Interstitial implantation of radioisotopes.
Photodynamic therapy (under clinical evaluation).
Sources: Photodynamic therapy
Watchful waiting or active surveillance/active monitoring
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Asymptomatic patients of advanced age or with concomitant illness may warrant consideration of careful observation without immediate active treatment.[8-10] Watch and wait, observation, expectant management, and active surveillance/active monitoring are terms indicating a strategy that does not employ immediate therapy with curative intent. For more information, see the Watchful Waiting or Active Surveillance/Active Monitoring section.
Sources: 8 · 10 · Watchful Waiting or Active Surveillance/Active Monitoring
Evidence (observation with delayed hormonal therapy):
In a retrospective pooled analysis, 828 men with clinically localized prostate cancer were managed by initial conservative therapy with subsequent hormonal therapy given at the time of symptomatic disease progression.
In a retrospective pooled analysis, 828 men with clinically localized prostate cancer were managed by initial conservative therapy with subsequent hormonal therapy given at the time of symptomatic disease progression.
This study showed that the patients with grade 1 or grade 2 tumors experienced a disease-specific survival of 87% at 10 years and that their overall survival (OS) closely approximated the expected survival among men of similar ages in the general population.[8]
Sources: 8
Radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radical prostatectomy, usually with pelvic lymphadenectomy (with or without the nerve-sparing technique designed to preserve potency) is the most commonly applied therapy with curative intent.[11-13] Radical prostatectomy may be difficult after a transurethral resection of the prostate (TURP).
Because about 40% to 50% of men with clinically organ-confined disease are found to have pathological extension beyond the prostate capsule or surgical margins, the role of postprostatectomy adjuvant radiation therapy has been studied.
Consideration may also be given to postoperative radiation therapy (PORT) for patients who are found to have seminal vesicle invasion by tumor at the time of prostatectomy or who have a detectable level of PSA more than 3 weeks after surgery.[14-16] Because duration of follow-up in available studies is still relatively short, the value of PORT has not been determined; however, PORT does reduce local recurrence.[14] Careful treatment planning is necessary to avoid morbidity.
Evidence (radical prostatectomy followed by radiation therapy):
In a randomized trial of 425 men with pathological T3, N0, and M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[15][Level of evidence A1]
Sources: 15 · Level of evidence A1
In a randomized trial of 425 men with pathological T3, N0, and M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[15][Level of evidence A1]
The primary end point, metastasis-free survival, could be affected by serial PSA monitoring and resulting metastatic work-up for PSA increase. This could have biased the primary end point in favor of radiation therapy, which was associated with a lower rate of PSA rise. Nevertheless, metastasis-free survival was not statistically different between the two study arms (P = .06). After a median follow-up of about 10.6 years, the overall median survival was 14.7 years in the radiation therapy group versus 13.8 years in the observation group (P = .16).
Although the OS rates were not statistically different, complication rates were substantially higher in the radiation therapy group: overall complications were 23.8% versus 11.9%, rectal complications were 3.3% versus 0%, and urethral stricture was 17.8% versus 9.5%.
After a median follow-up of about 12.5 years, however, OS was better in the radiation therapy arm; hazard ratio (HR)death, 0.72 (95% confidence interval [CI], 0.55–0.96; P = .023). The 10-year estimated survival rates were 74% in the radiation therapy arm and 66% in the control arm. The 10-year estimated metastasis-free survivals were 73% and 65% (P = .016).[16][Level of evidence A1]
Sources: 16 · Level of evidence A1
Another randomized trial came to a different conclusion with respect to the effect of postoperative radiation therapy on OS.[17][Level of evidence A1] In the European Organisation for Research and Treatment of Cancer (EORTC) trial (EORTC-22911 [NCT00002511]), 1,005 men aged 75 years and younger with clinical T0 to T3 prostate cancer were randomly assigned after prostatectomy to receive PORT (60 Gy) or observation, with subsequent therapy delayed until the occurrence of either biochemical or clinical relapse. The recommended treatment for local recurrence was radiation.
Sources: 17 · Level of evidence A1 · EORTC-22911
Another randomized trial came to a different conclusion with respect to the effect of postoperative radiation therapy on OS.[17][Level of evidence A1] In the European Organisation for Research and Treatment of Cancer (EORTC) trial (EORTC-22911 [NCT00002511]), 1,005 men aged 75 years and younger with clinical T0 to T3 prostate cancer were randomly assigned after prostatectomy to receive PORT (60 Gy) or observation, with subsequent therapy delayed until the occurrence of either biochemical or clinical relapse. The recommended treatment for local recurrence was radiation.
With a median follow-up of 10.6 years (up to 16.6 years), the biochemical progression-free survival (PFS) rates were higher in the observation study arm (60.6% vs. 41.1%; HR, 0.49; 95% CI, 0.41–0.59; P < .0001). Locoregional relapse rates were 8.4% versus 17.3% in favor of immediate radiation (HR, 0.45; 95% CI, 0.32–0.68; P < .0001).
However, the large differences in biochemical relapse-free survival and local recurrence did not translate into an advantage in either distant metastasis (11.0% vs. 11.3%; HR, 0.99; 95% CI, 0.67–1.44; P = .94) or in OS (76.9% with immediate radiation vs. 80.7% with observation; HR, 1.18; 95% CI, 0.91–1.53; P = .2). Nor was there a difference in prostate– cancer-specific mortality (3.9% vs. 5.2%; HR, 0.78; 95% CI, 0.46–1.33; P = .34)
The 10-year cumulative risk of severe (grade 3) late toxicity in the immediate radiation study group was 5.3% versus 2.5% in the observation group (P = .052). Late adverse effects of any grade were also higher in the immediate radiation group (70.8% vs. 59.7%; P = .001).
Radical prostatectomy has been compared with watchful waiting or active surveillance/active monitoring. For more information, see the Radical prostatectomy compared with other treatment options section.
Sources: Radical prostatectomy compared with other treatment options
Evidence (radical prostatectomy compared with watchful waiting):
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407 [NCT00007644]) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy versus watchful waiting.[18-20][Level of evidence A1]
Sources: PIVOT-1 · 18 · 20 · Level of evidence A1
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407 [NCT00007644]) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy versus watchful waiting.[18-20][Level of evidence A1]
About 50% of the men had nonpalpable, screen-detected disease.
After a median follow-up of 12.7 years (range up to about 19.5 years), the all-cause mortality was 61.3% versus 66.8% in the prostatectomy and watchful-waiting study arms, respectively, an absolute difference of 5.5 percentage points (95% CI -1.5 to 12.4) that was not statistically significant (HR, 0.84; 95% CI, 0.70–1.01). Prostate–cancer-specific mortality was 7.4% versus 11.4%, and it also was not statistically significant (HR, 0.63; 95% CI, 0.3–1.02).
Although treatment for disease progression was given more frequently in the observation arm of the study, most of the treatment was for asymptomatic, local, or biochemical (PSA) progression.
As expected, urinary incontinence and erectile/sexual dysfunction was more common in the prostatectomy group for at least 10 years of follow-up. Absolute differences in patient-reported use of absorbent urinary pads was greater in the surgery group by more than 30 percentage points at all time points for at least 10 years. Disease- or treatment-related limitations in activities of daily living were worse with surgery than with observation through 2 years, but then were similar in both study arms.
External-beam radiation therapy (EBRT)
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
EBRT is another treatment option used with curative intent.[21-25] Definitive radiation therapy should be delayed 4 to 6 weeks after TURP to reduce the incidence of stricture.[26] Adjuvant hormonal therapy should be considered for patients with bulky T2b to T2c tumors.[27,28]
Evidence (EBRT with or without adjuvant hormonal therapy):
In the Radiation Therapy Oncology Group (RTOG) trial RTOG-7706, prophylactic radiation therapy to clinically or pathologically uninvolved pelvic lymph nodes did not appear to improve OS or prostate cancer-specific survival.[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
The phase III randomized RTOG-9413 trial (NCT00769548) included 1,323 men with localized prostate cancer, an elevated PSA, and an estimated risk of lymph node involvement of 15%. Patients were randomly assigned to one of four treatment arms: whole-pelvic radiation therapy plus neoadjuvant and concurrent hormonal therapy; prostate-only radiation therapy plus neoadjuvant and concurrent hormonal therapy; whole-pelvic radiation therapy plus adjuvant hormonal therapy; or pelvic-only radiation therapy plus adjuvant hormonal therapy.[30]; [31][Level of evidence B1]
Sources: RTOG-9413 · 30 · 31 · Level of evidence B1
The phase III randomized RTOG-9413 trial (NCT00769548) included 1,323 men with localized prostate cancer, an elevated PSA, and an estimated risk of lymph node involvement of 15%. Patients were randomly assigned to one of four treatment arms: whole-pelvic radiation therapy plus neoadjuvant and concurrent hormonal therapy; prostate-only radiation therapy plus neoadjuvant and concurrent hormonal therapy; whole-pelvic radiation therapy plus adjuvant hormonal therapy; or pelvic-only radiation therapy plus adjuvant hormonal therapy.[30]; [31][Level of evidence B1]
Although RTOG-9413 showed increased PFS at 4 years for patients who had a 15% estimated risk of lymph node involvement and received whole-pelvic radiation therapy compared with prostate-only radiation therapy, OS and PSA failure rates were not significantly different.
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of a luteinizing hormone-releasing hormone agonist plus long-term flutamide (250 mg PO tid) with or without EBRT.[28][Level of evidence A1]
Sources: 28 · Level of evidence A1
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of a luteinizing hormone-releasing hormone agonist plus long-term flutamide (250 mg PO tid) with or without EBRT.[28][Level of evidence A1]
Nineteen percent of the men had tumor stage T2, and 78% of the men had T3. At 10 years, both overall mortality (29.6% vs. 39.4%; 95% CI for the difference, 0.8%–18.8%) and the prostate–cancer-specific mortality (11.9% vs. 23.9%; 95% CI for the difference, 4.9%–19.1%) favored combined hormonal and radiation therapy.
Although flutamide might not be considered a standard hormonal monotherapy in the setting of T2 or T3 tumors, radiation therapy provided a disease-free survival or tumor-specific survival advantage even though this monotherapy was applied. This analysis rests on the assumption that flutamide does not shorten life expectancy and cancer-specific survival. Radiation therapy was not delivered by current standards of dose and technique.
Interstitial implantation of radioisotopes
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Interstitial implantation of radioisotopes (i.e., iodine I 125 [125I], palladium, and iridium Ir 192) done through a transperineal technique with either ultrasound or computed-tomography guidance, is being used in patients with T1 or T2a tumors. Short-term results in these patients are similar to those for radical prostatectomy or EBRT.[32,33]; [34][Level of evidence C3]
Sources: 32 · 33 · 34 · Level of evidence C3
Factors for consideration in the use of interstitial implants include:
The implant is performed as outpatient surgery.
The rate of maintenance of sexual potency with interstitial implants has been reported to be 86% to 92%.[32,34] In contrast, rates of maintenance of sexual potency with radical prostatectomy were 10% to 40% and 40% to 60% with EBRT.
Typical side effects from interstitial implants that subside with time include urinary tract frequency, urgency, and less commonly, urinary retention.
Rectal ulceration may also be seen. In one series, a 10% 2-year actuarial genitourinary grade 2 complication rate and a 12% risk of rectal ulceration were seen. This risk decreased with increased operator experience and modification of the implant technique.[32]
Sources: 32
Long-term follow-up of these patients is necessary to assess treatment efficacy and side effects.
Photodynamic therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Vascular-targeted photodynamic therapy using a photosensitizing agent has been tested in men with low-risk prostate cancer. In the CLIN1001 PCM301 (NCT01310894) randomized trial, 413 men with low-risk cancer (tumor stage T1–T2c, PSA ≤10 ng/mL, generally Gleason score 3 + 3) were randomly assigned in an open-label trial to receive either the photosensitizing agent, padeliporfin (4 mg/kg intravenously [IV] over 10 minutes, and optical fibers inserted into the target area of the prostate, then activated by 753 nm laser light at 150 mW/cm for 22 minutes 15 seconds), or active surveillance.[37] Median time to local disease progression was 28.3 months for patients who received padeliporfin and 14.1 months for patients who were assigned to active surveillance (HR, 0.34; 95% CI, 0.24–0.46; P < .0001).[37][Level of evidence B1] However, the appropriate population for photodynamic therapy may be quite narrow, as it may overtreat men with very low-risk disease and undertreat men with higher-risk disease.[38]
Sources: CLIN1001 PCM301 · 37 · 37 · Level of evidence B1 · 38
Treatment of Stage II Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Overview
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Stage II prostate cancer is defined by the American Joint Committee on Cancer's TNM (tumor, node, metastasis) classification system:[1]
Sources: 1
Stage IIA
cT1a–c, N0, M0, prostate-specific antigen (PSA) ≥10 <20 ng/mL, Gleason ≤6.
cT2a, N0, M0, PSA ≥10 <20 ng/mL, Gleason ≤6.
pT2, N0, M0, PSA ≥10 <20 ng/mL, Gleason ≤6.
cT2b–c, N0, M0, PSA <20 ng/mL, Gleason ≤6.
Stage IIB
T1–2, N0, M0, PSA <20 ng/mL, Gleason 7.
Stage IIC
T1–2, N0, M0, PSA <20, Gleason 7 or 8.
Radical prostatectomy, external-beam radiation therapy (EBRT), and interstitial implantation of radioisotopes are each employed in the treatment of stage II prostate cancer with apparently similar therapeutic effects. Radical prostatectomy and radiation therapy yield apparently similar survival rates with as many as 10 years of follow-up. For well-selected patients, radical prostatectomy is associated with a 15-year survival comparable with an age-matched population without prostate cancer.[2] Unfortunately, randomized comparative trials of these treatment methods with prolonged follow-up are lacking.
Sources: 2
Patients with a small, palpable cancer (T2a, N0, and M0) fare better than patients in whom the disease involves both sides of the gland (T2c, N0, and M0). Patients proven free of node metastases by pelvic lymphadenectomy fare better than patients in whom this staging procedure is not performed; however, this is the result of selection of patients who have a more favorable prognosis.
Side effects of the various forms of therapy—including impotence, incontinence, and bowel injury—should be considered in determining the type of treatment to employ.
Prostate-specific antigen (PSA) changes as markers of tumor progression
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Often, changes in PSA are thought to be markers of tumor progression. Even though a tumor marker or characteristic may be consistently associated with a high risk of prostate cancer progression or death, it may be a very poor predictor of very limited utility in making therapeutic decisions.
Baseline PSA and rate of PSA change were associated with subsequent metastasis or prostate cancer death in a cohort of 267 men with clinically localized prostate cancer who were managed by watchful waiting or active surveillance in the control arm of a randomized trial comparing radical prostatectomy with watchful waiting.[3,4] Nevertheless, the accuracy of classifying men into groups whose cancer remained indolent versus those whose cancer progressed was poor at all examined cut points of PSA or PSA rate of change.
Bisphosphonates and risk of bone metastases
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Patients with locally advanced nonmetastatic disease (T2–T4, N0–N1, and M0) are at risk of developing bone metastases. Bisphosphonates are being studied as a strategy to decrease this risk.
Evidence (bisphosphonates and risk of bone metastases):
A placebo-controlled randomized trial (MRC-PR04) evaluated a 5-year regimen of the first-generation bisphosphonate clodronate in high oral doses (2,080 mg qd). Clodronate therapy had no favorable impact on either time to symptomatic bone metastasis or survival.[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
Treatment Options for Stage II Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for patients with stage II prostate cancer include:
Sources: stage II prostate cancer
Watchful waiting or active surveillance/active monitoring.
Sources: Watchful waiting or active surveillance/active monitoring
Radical prostatectomy.
Sources: Radical prostatectomy
External-beam radiation therapy (EBRT) with or without hormonal therapy.
Sources: External-beam radiation therapy (EBRT) with or without hormonal therapy
Interstitial implantation of radioisotopes.
Ultrasound-guided percutaneous cryosurgery (under clinical evaluation).
High-intensity focused ultrasound (under clinical evaluation).
Sources: High-intensity focused ultrasound
Proton-beam radiation therapy (under clinical evaluation).
Sources: Proton-beam radiation therapy
Photodynamic therapy (under clinical evaluation).
Sources: Photodynamic therapy
Patients with stage II prostate cancer are candidates for clinical trials, including trials of neoadjuvant hormonal therapy followed by radical prostatectomy.
Watchful waiting or active surveillance/active monitoring
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Asymptomatic patients of advanced age or with concomitant illness may warrant consideration of careful observation without immediate active treatment.[6-8] Watch and wait, observation, expectant management, and active surveillance/active monitoring are terms indicating a strategy that does not employ immediate therapy with curative intent. For more information, see the Treatment Option Overview for Prostate Cancer section.
Sources: 6 · 8 · Treatment Option Overview for Prostate Cancer
Evidence (observation with delayed hormonal therapy):
In a retrospective pooled analysis, 828 men with clinically localized prostate cancer were managed by initial conservative therapy with subsequent hormonal therapy given at the time of symptomatic disease progression.[6]
Sources: 6
In a retrospective pooled analysis, 828 men with clinically localized prostate cancer were managed by initial conservative therapy with subsequent hormonal therapy given at the time of symptomatic disease progression.[6]
Patients with well-differentiated tumors or moderately well-differentiated tumors experienced a disease-specific survival of 87% at 10 years. Overall survival (OS) closely approximated the expected survival among men of similar ages in the general population.
The decision to treat should be made in the context of the patient’s age, associated medical illnesses, and personal desires.
Radical prostatectomy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radical prostatectomy, usually with pelvic lymphadenectomy (with or without the nerve-sparing technique designed to preserve potency) is the most commonly applied therapy with curative intent.[2,9,10] Radical prostatectomy may be difficult after a transurethral resection of the prostate (TURP).
Because about 40% to 50% of men with clinically organ-confined disease are found to have pathological extension beyond the prostate capsule or surgical margins, the role of postprostatectomy adjuvant radiation therapy has been studied.
Consideration may also be given to postoperative radiation therapy (PORT) for patients who are found to have seminal vesicle invasion by tumor at the time of prostatectomy or who have a detectable level of PSA more than 3 weeks after surgery.[11-13] Because the duration of follow-up in available studies is relatively short, the value of PORT has not been determined; however, PORT does reduce local recurrence.[11] Careful treatment planning is necessary to avoid morbidity.
Evidence (radical prostatectomy followed by radiation therapy):
In a randomized trial of 425 men with pathological T3, N0, M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
In a randomized trial of 425 men with pathological T3, N0, M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[12][Level of evidence A1]
The primary end point, metastasis-free survival, could be affected by serial PSA monitoring and resulting metastatic work-up for PSA increase. This could have biased the primary end point in favor of radiation therapy, which was associated with a lower rate of PSA rise. Nevertheless, metastasis-free survival was not statistically different between the two study arms (P = .06). After a median follow-up of about 10.6 years, overall median survival was 14.7 years in the radiation therapy group versus 13.8 years in the observation group (P = .16).
Although the OS rates were not statistically different, complication rates were substantially higher in the radiation therapy group compared with the observation group: overall complications were 23.8% versus 11.9%, rectal complications were 3.3% versus 0%, and urethral stricture was 17.8% versus 9.5%, respectively.
After a median follow-up of about 12.5 years, however, OS was better in the radiation therapy arm; hazard ratio (HR)death, 0.72 (95% confidence interval [CI], 0.55–0.96; P = .023). The 10-year estimated survival rates were 74% in the radiation therapy arm and 66% in the control arm. The 10-year estimated metastasis-free survivals were 73% and 65% (P = .016).[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
Evidence (radical prostatectomy compared directly with watchful waiting/active surveillance/active monitoring and/or external-beam radiation therapy):
In a randomized clinical trial performed in Sweden in the pre-PSA screening era, 695 men with prostate cancer were randomly assigned to radical prostatectomy versus watchful waiting. Only about 5% of the men in the trial had been diagnosed by PSA screening. Therefore, the men had more extensive local disease than is typically the case in men diagnosed with prostate cancer in the United States.[14-16]
In a randomized clinical trial performed in Sweden in the pre-PSA screening era, 695 men with prostate cancer were randomly assigned to radical prostatectomy versus watchful waiting. Only about 5% of the men in the trial had been diagnosed by PSA screening. Therefore, the men had more extensive local disease than is typically the case in men diagnosed with prostate cancer in the United States.[14-16]
The cumulative overall mortality at 18 years was 56.1% in the radical prostatectomy arm and 68.9% in the watchful waiting study arm (absolute difference, 12.7%; 95% CI, 5.1–20.3 percentage points; relative risk [RR]death, 0.71; 95% CI, 0.59–0.86.[16][Level of evidence A1]
Sources: 16 · Level of evidence A1
The cumulative incidence of prostate cancer deaths at 18 years was 17.7% versus 28.7% (absolute difference, 11.0%; 95% CI, 4.5–17.5 percentage points; RRdeath from prostate cancer, 0.56; 95% CI, 0.41–0.77).[16]
Sources: 16
In a post-hoc–subset analysis, the improvement in overall and prostate cancer-specific mortality associated with radical prostatectomy was restricted to men younger than 65 years.
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy versus watchful waiting.[17-19][Level of evidence A1]
Sources: PIVOT-1 · 17 · 19 · Level of evidence A1
The Prostate Intervention Versus Observation Trial (PIVOT-1 or VA-CSP-407) is a randomized trial conducted in the PSA screening era that directly compared radical prostatectomy with watchful waiting. From November 1994 through January 2002, 731 men aged 75 years or younger with localized prostate cancer (stage T1–2, NX, M0, with a blood PSA <50 ng/mL) and a life expectancy of at least 10 years were randomly assigned to radical prostatectomy versus watchful waiting.[17-19][Level of evidence A1]
About 50% of the men had palpable tumors.
After a median follow-up of 12.7 years (range up to about 19.5 years), the all-cause mortality was 61.3% versus 66.8% in the radical-prostatectomy and watchful-waiting study arms, respectively, an absolute difference of 5.5 percentage points (95% CI -1.5 to 12.4) that was not statistically significant (HR, 0.84; 95% CI, 0.70–1.01). Prostate cancer–specific mortality was 7.4% versus 11.4%, and it also was not statistically significant (HR, 0.63; 95% CI, 0.3–1.02).
Although treatment for disease progression was given more frequently in the observation arm of the study, most such treatment was for asymptomatic, local, or biochemical (PSA) progression.
As expected, urinary incontinence and erectile/sexual dysfunction was more common in the prostatectomy group for at least 10 years of follow-up. Absolute differences in patient-reported use of absorbent urinary pads was greater in the surgery group by more than 30 percentage points at all time points for at least 10 years. Disease- or treatment-related limitations in activities of daily living were worse with surgery than with observation through 2 years, but then were similar in both study arms.
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3D conformal radiation (74 Gy in 37 fractions). The primary end point was prostate cancer-specific mortality.[20]
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3D conformal radiation (74 Gy in 37 fractions). The primary end point was prostate cancer-specific mortality.[20]
With a median follow-up of 10 years, there were a total of 17 deaths from prostate cancer, with no statistically significant differences among the three study arms (P = .48). The 10-year prostate cancer–specific survival rates were 98.8% in the active monitoring arm, 99.0% in the radical prostatectomy arm, and 99.6% radiation therapy arms.[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
Likewise, all-cause mortality was nearly identical in all three study arms: 10.9 deaths in the active monitoring arm, 10.1 in the radical prostatectomy arm, and 10.3 in the radiation therapy arm per 1,000 person-years (P = .87).[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
There were statistically significant differences in progression to metastatic disease among the treatment arms (33 of 545 men in the active monitoring arm; 13 of 553 men in the radical prostatectomy arm; 16 of 545 men in the radiation therapy arm) that began to emerge after 4 years, but these differences had not translated into any difference in mortality after 10-years of follow-up. Over the course of 10 years, 52% of the patients required active intervention.
As expected, there were substantial differences in patient-reported outcomes among the three management approaches.[21][Level of evidence A3] A substudy of patient-reported outcomes up to 6 years after randomization reported the following results:
Sources: 21 · Level of evidence A3
In the ProtecT trial (NCT02044172 and ISRCTN20141297), 82,429 men were screened with PSA testing, and 2,664 were diagnosed with clinically localized prostate cancer. Among those diagnosed, 1,643 men (median age 62 years, range 50–69 years) consented to a randomly assigned comparison of active monitoring, radical prostatectomy (nerve-sparing when possible), or external-beam 3D conformal radiation (74 Gy in 37 fractions). The primary end point was prostate cancer-specific mortality.[20] › As expected, there were substantial differences in patient-reported outcomes among the three management approaches.[21][Level of evidence A3] A substudy of patient-reported outcomes up to 6 years after randomization reported the following results:
Men in the radical prostatectomy study arm had substantial rates of urinary incontinence (e.g., using one or more absorbent pads qd was reported by 46% at 6 months and by 17% at year 6) with very little incontinence in the other two study arms.
Sexual function was also worse in the radical prostatectomy group (e.g., at 6 months, 12% of men reported erections firm enough for intercourse vs. 22% in the radiation therapy arm and 52% in the active-monitoring arm).
Bowel function, however, was worse in the radiation therapy arm (e.g., about 5% reported bloody stools at least half the time at 2 years and beyond versus none in the radical prostatectomy and active-monitoring study arms).
External-beam radiation therapy (EBRT) with or without hormonal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
EBRT is another treatment option often used with curative intent.[22-26] Definitive radiation therapy should be delayed 4 to 6 weeks after TURP to reduce the incidence of stricture.[27] Adjuvant hormonal therapy should be considered for patients with bulky T2b to T2c tumors.[28]
The role of adjuvant hormonal therapy in patients with locally advanced disease has been analyzed by the Agency for Health Care Policy and Research (now the Agency for Healthcare Research and Quality). Most patients had more advanced disease, but patients with bulky T2b to T2c tumors were included in the studies that were re-evaluating the role of adjuvant hormonal therapy in patients with locally advanced disease.
Evidence (EBRT with or without adjuvant hormonal therapy):
The Radiation Therapy Oncology Group's (RTOG) trial 7706 (RTOG-7706).[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
The Radiation Therapy Oncology Group's (RTOG) trial 7706 (RTOG-7706).[29][Level of evidence A1]
Prophylactic radiation therapy to clinically or pathologically uninvolved pelvic lymph nodes does not appear to improve OS or prostate cancer-specific survival.
RTOG-9413 (RTOG-9413 [NCT00769548]) trial.[30,31][Level of evidence B1]
Sources: RTOG-9413 · 30 · 31 · Level of evidence B1
RTOG-9413 (RTOG-9413 [NCT00769548]) trial.[30,31][Level of evidence B1]
Although RTOG-9413 showed increased progression-free survival at 4 years for patients who had a 15% estimated risk of lymph node involvement and received whole-pelvic radiation therapy compared with prostate-only radiation therapy, OS and PSA failure rates were not significantly different.
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of a luteinizing hormone-releasing hormone (LH-RH) agonist plus long-term flutamide (250 mg PO tid) with or without EBRT.[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of a luteinizing hormone-releasing hormone (LH-RH) agonist plus long-term flutamide (250 mg PO tid) with or without EBRT.[32][Level of evidence A1]
Nineteen percent of the men had tumor stage T2, and 78% of the men had tumor stage T3. At 10 years, both overall mortality (29.6% vs. 39.4%; 95% CI for the difference, 0.8%–18.8%) and prostate cancer-specific mortality (11.9% vs. 23.9%; 95% CI for the difference, 4.9%–19.1%) favored combined hormonal and radiation therapy.
Although flutamide might not be considered a standard hormonal monotherapy in the setting of T2 or T3 tumors, radiation therapy provided a disease-free survival or tumor-specific survival advantage even though this monotherapy was applied. This analysis rests on the assumption that flutamide does not shorten life expectancy and cancer-specific survival. Radiation therapy was not delivered by current standards of dose and technique.
Another trial compared androgen deprivation therapy (ADT: an LH-RH agonist or orchiectomy) with ADT plus radiation therapy (65–69 Gy to the prostate by 4-field box technique, including 45 Gy to the whole pelvis, seminal vesicles, and external/internal iliac nodes unless the lymph nodes were histologically negative). This trial, NCIC CTG PR.3/MRC UKPRO7 [NCT00002633], from the National Cancer Institute of Canada randomly assigned 1,205 patients with high-risk (PSA >40 ng/mL or PSA >20 ng/mL and Gleason score ≥8), T2 (12%–13% of the patients), T3 (83% of the patients), and T4 (4%–5% of the patients) with clinical or pathologically staged N0, M0 disease.[33,34][Level of evidence A1]
Sources: NCIC CTG PR.3/MRC UKPRO7 · 33 · 34 · Level of evidence A1
Another trial compared androgen deprivation therapy (ADT: an LH-RH agonist or orchiectomy) with ADT plus radiation therapy (65–69 Gy to the prostate by 4-field box technique, including 45 Gy to the whole pelvis, seminal vesicles, and external/internal iliac nodes unless the lymph nodes were histologically negative). This trial, NCIC CTG PR.3/MRC UKPRO7 [NCT00002633], from the National Cancer Institute of Canada randomly assigned 1,205 patients with high-risk (PSA >40 ng/mL or PSA >20 ng/mL and Gleason score ≥8), T2 (12%–13% of the patients), T3 (83% of the patients), and T4 (4%–5% of the patients) with clinical or pathologically staged N0, M0 disease.[33,34][Level of evidence A1]
At a median follow-up of 8 years (maximum, 13 years), OS was superior in the ADT-plus-radiation therapy group (HRdeath, 0.77; 95% CI, 0.57–0.85, P = .001). The OS rate at 10 years was 55% for the ADT-plus-radiation therapy group versus 49% for the ADT-alone group.
Although radiation therapy had the expected bowel and urinary side effects, quality of life was the same in each study group by 24 months and beyond.[35]
Sources: 35
A meta-analysis of randomized clinical trial evidence comparing radiation therapy with radiation therapy plus prolonged androgen suppression has been published. The meta-analysis found a difference in 5-year OS in favor of radiation therapy plus continued androgen suppression (LH-RH agonist or orchiectomy) as compared with radiation therapy alone (HR, 0.631; 95% CI, 0.479–0.831).[28][Level of evidence A1]
Sources: 28 · Level of evidence A1
In a randomized, prospective clinical trial, 18 months of androgen suppression with an LH-RH agonist appears to have provided results that were similar to 36 months with respect to OS and disease-specific survival.[36][Level of evidence A1] In a multicenter trial, 630 men with stage II to stage IVA cancer (clinical stage T3–T4, or PSA >20 ng/ml, or Gleason score >7) received 70 Gy of radiation in 35 fractions plus a total of either 18 or 36 months of goserelin acetate.
Sources: 36 · Level of evidence A1
In a randomized, prospective clinical trial, 18 months of androgen suppression with an LH-RH agonist appears to have provided results that were similar to 36 months with respect to OS and disease-specific survival.[36][Level of evidence A1] In a multicenter trial, 630 men with stage II to stage IVA cancer (clinical stage T3–T4, or PSA >20 ng/ml, or Gleason score >7) received 70 Gy of radiation in 35 fractions plus a total of either 18 or 36 months of goserelin acetate.
With a median follow-up of 9.4 years, OS was nearly identical in each study arm (62% at 10 years; HRdeath, 1.02; 95% CI, 0.81–1.29; P = .8), as was prostate cancer–specific survival (HRprostate death, 0.95; 95% CI, 0.58–0.55; P = .8).
Global quality of life was nearly identical on both study arms, but sexual activity and interest in sex was moderately better in the 18-month arm.[36][Level of evidence A3]
Sources: 36 · Level of evidence A3
A meta-analysis of seven randomized controlled trials comparing early hormonal treatment (adjuvant or neoadjuvant) to deferred hormonal treatment (LH-RH agonists and/or antiandrogens) in patients with locally advanced prostate cancer, whether treated with prostatectomy, radiation therapy, or watchful waiting or active surveillance/active monitoring, showed improved overall mortality for patients receiving early treatment (RR, 0.86; 95% CI, 0.82–0.91).[37][Level of evidence A1]
Sources: 37 · Level of evidence A1
Short-term neoadjuvant−androgen therapy administered before and during radiation therapy has shown benefit in at least some patients with clinically localized prostate cancer. In an open-label, randomized trial (RTOG-9408 [NCT00002597]), 1,979 men with nonmetastatic stage T1b–c, T2a, or T2b tumors and a PSA level of 20 ng/mL or less were randomly assigned to receive radiation therapy (66.6 Gy prostate dose in 1.8 Gy daily fractions) with or without 4 months of ADT (flutamide 250 mg PO tid plus either monthly goserelin 3.6 mg subcutaneously (SQ) or leuprolide 7.5 mg intramuscularly), beginning 2 months before radiation therapy. Median follow-up was about 9 years.[38][Level of evidence A1]
Sources: RTOG-9408 · 38 · Level of evidence A1
Short-term neoadjuvant−androgen therapy administered before and during radiation therapy has shown benefit in at least some patients with clinically localized prostate cancer. In an open-label, randomized trial (RTOG-9408 [NCT00002597]), 1,979 men with nonmetastatic stage T1b–c, T2a, or T2b tumors and a PSA level of 20 ng/mL or less were randomly assigned to receive radiation therapy (66.6 Gy prostate dose in 1.8 Gy daily fractions) with or without 4 months of ADT (flutamide 250 mg PO tid plus either monthly goserelin 3.6 mg subcutaneously (SQ) or leuprolide 7.5 mg intramuscularly), beginning 2 months before radiation therapy. Median follow-up was about 9 years.[38][Level of evidence A1]
The 10-year OS rate was 57% in the radiation-only group versus 62% in the combined-therapy group (HRdeath, 1.17; 95% CI, 1.01–1.35; P = .03).
In a post-hoc analysis, there was no statistically significant interaction between the treatment effect and baseline-risk category of the patients. However, there appeared to be little, if any, benefit associated with combined therapy in the lowest-risk category of patients (Gleason score ≤6; PSA ≤10 ng/mL; and clinical stage ≤T2a).
The OS benefit was most apparent in men with intermediate-risk tumors (Gleason score 7; or Gleason score ≤6 and PSA >10 ng/mL; or clinical stage T2b).
The duration of neoadjuvant hormonal therapy has been tested in a randomized trial (TROG 96.01 [ACTRN12607000237482]) involving 818 men with locally advanced (T2b, T2c, T3, and T4) nonmetastatic cancer treated with radiation therapy (i.e., 66 Gy in 2 Gy daily fractions to the prostate and seminal vesicles but not including regional lymph nodes).[39] In an open-label design, patients were randomly assigned to receive radiation therapy alone, 3 months of neoadjuvant androgen deprivation therapy (NADT) (goserelin 3.6 mg SQ each month plus flutamide 250 mg PO tid) for 2 months before and during radiation, or 6 months of NADT for 5 months before and during radiation.[39][Level of evidence A1]
Sources: 39 · 39 · Level of evidence A1
The duration of neoadjuvant hormonal therapy has been tested in a randomized trial (TROG 96.01 [ACTRN12607000237482]) involving 818 men with locally advanced (T2b, T2c, T3, and T4) nonmetastatic cancer treated with radiation therapy (i.e., 66 Gy in 2 Gy daily fractions to the prostate and seminal vesicles but not including regional lymph nodes).[39] In an open-label design, patients were randomly assigned to receive radiation therapy alone, 3 months of neoadjuvant androgen deprivation therapy (NADT) (goserelin 3.6 mg SQ each month plus flutamide 250 mg PO tid) for 2 months before and during radiation, or 6 months of NADT for 5 months before and during radiation.[39][Level of evidence A1]
After a median follow-up of 10.6 years, there were no statistically significant differences between the radiation-alone group and the radiation-plus-3-months-of NADT group.
However, the 6-month NADT arm showed better prostate–cancer-specific mortality and overall mortality than the radiation-alone group; 10-year all-cause mortality 29.2% versus 42.5% (HR, 0.63; 95% CI, 0.48–0.83, P = .0008).
The duration of neoadjuvant hormonal therapy was tested in another trial (RTOG-9910 [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason score 7, and PSA <20; or T1b–1c, Gleason score 8–10, and PSA <20) and no evidence of metastases. The men were randomly assigned to receive short-course neoadjuvant–androgen suppression (an LH-RH agonist plus bicalutamide or flutamide for 8 weeks before and 8 weeks during radiation therapy) or long-course neoadjuvant–androgen suppression (28 weeks before and 8 weeks during radiation therapy). Both groups received 70.2 Gy radiation in 39 daily fractions to the prostate and 46.8 Gy to the iliac lymph nodes.[40][Level of evidence A1]
Sources: RTOG-9910 · 40 · Level of evidence A1
The duration of neoadjuvant hormonal therapy was tested in another trial (RTOG-9910 [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason score 7, and PSA <20; or T1b–1c, Gleason score 8–10, and PSA <20) and no evidence of metastases. The men were randomly assigned to receive short-course neoadjuvant–androgen suppression (an LH-RH agonist plus bicalutamide or flutamide for 8 weeks before and 8 weeks during radiation therapy) or long-course neoadjuvant–androgen suppression (28 weeks before and 8 weeks during radiation therapy). Both groups received 70.2 Gy radiation in 39 daily fractions to the prostate and 46.8 Gy to the iliac lymph nodes.[40][Level of evidence A1]
After a median of 9.4 years, 10-year prostate-specific mortality, the primary end point, was low in both study arms: 5% versus 4% (HR, 0.81; 95% CI, 0.48–1.39).[40][Level of evidence A1]
Sources: 40 · Level of evidence A1
No statistically significant differences in overall mortality or in locoregional disease progression were found.[40][Level of evidence A1]
Sources: 40 · Level of evidence A1
There was also no apparent differential effect of androgen suppression duration among any of the risk-group subsets.
Addition of androgen suppression therapy to EBRT may benefit men who are at an elevated risk of disease recurrence and death from prostate cancer (RTOG-9202 [NCT00767286]).
Sources: RTOG-9202
Interstitial implantation of radioisotopes
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Interstitial implantation of radioisotopes (i.e., iodine I 125 [125I], palladium, and iridium), using a transperineal technique with either ultrasound or computed tomography guidance, is being done in patients with T1 or T2a tumors. Short-term results in these patients are similar to those for radical prostatectomy or EBRT.[41,42]; [43][Level of evidence C3]
Sources: 41 · 42 · 43 · Level of evidence C3
Factors for consideration in the use of interstitial implants include:
The implant is performed as outpatient surgery.
The rate of maintenance of sexual potency with interstitial implants has been reported to be 86% to 92%.[41,43] In contrast, rates of maintenance of sexual potency with radical prostatectomy were 10% to 40% and 40% to 60% with EBRT.
Typical side effects from interstitial implants that are seen in most patients but subside with time include urinary tract frequency, urgency, and less commonly, urinary retention.
Rectal ulceration may also be seen.[41] In one series, a 10% 2-year actuarial genitourinary grade 2 complication rate and a 12% risk of rectal ulceration were seen. This risk decreased with increased operator experience and modification of the implant technique.[44]
Long-term follow-up of these patients is necessary to assess treatment efficacy and side effects.
Ultrasound-guided percutaneous cryosurgery
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Cryosurgery is a surgical technique that involves destruction of prostate cancer cells by intermittent freezing of the prostate with cryoprobes followed by thawing.[46][Level of evidence C1]; [47,48][Level of evidence C3] Cryosurgery is less well established than standard prostatectomy, and long-term outcomes are not as well established as with prostatectomy or radiation therapy. Serious toxic effects include:
Sources: 46 · Level of evidence C1 · 47 · 48 · Level of evidence C3
Bladder outlet injury.
Urinary incontinence.
Sexual impotence.
Rectal injury.
High-intensity focused ultrasound
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Proton-beam radiation therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
There is growing interest in the use of proton-beam radiation therapy for the treatment of prostate cancer. Although the dose distribution of this form of charged-particle radiation has the potential to improve the therapeutic ratio of prostate radiation, allowing for an increase in dose to the tumor without a substantial increase in side effects, no randomized controlled trials have been reported that compare its efficacy and toxicity with those of other forms of radiation therapy.
Photodynamic therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Vascular-targeted photodynamic therapy using a photosensitizing agent has been tested in men with low-risk prostate cancer. In the CLIN1001 PCM301 (NCT01310894) randomized trial, 413 men with low-risk cancer (tumor stage T1–T2c, PSA ≤10 ng/mL, generally Gleason score 3 + 3) were randomly assigned in an open-label trial to receive either the photosensitizing agent, padeliporfin (4 mg/kg IV over 10 minutes, and optical fibers inserted into the target area of the prostate, then activated by 753 nm laser light at 150 mW/cm for 22 minutes 15 seconds), or active surveillance.[52] Median time to local disease progression was 28.3 months for patients who received padeliporfin and 14.1 months for patients who were assigned to active surveillance (HR, 0.34; 95% CI, 0.24–0.46; P < .0001).[52][Level of evidence B1] However, the appropriate population for photodynamic therapy may be quite narrow, as it may overtreat men with very low-risk disease and undertreat men with higher-risk disease.[53]
Sources: CLIN1001 PCM301 · 52 · 52 · Level of evidence B1 · 53
Treatment of Stage III Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Overview
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Stage III prostate cancer is defined by the American Joint Committee on Cancer's TNM (tumor, node, metastasis) classification system:[1]
Sources: 1
Stage IIIA
T1–2, N0, M0, prostate-specific antigen (PSA) ≥20, Gleason ≤6–8.
Stage IIIB
T3–4, N0, M0, any PSA, Gleason ≤6–8.
Stage IIIC
Any T, N0, M0, any PSA, Gleason 9 or 10.
Extraprostatic extension with microscopic bladder neck invasion (T4) is included with T3a.
External-beam radiation therapy (EBRT), interstitial implantation of radioisotopes, and radical prostatectomy are used to treat stage III prostate cancer.[2] Prognosis is greatly affected by whether regional lymph nodes are evaluated and proven not to be involved.
Sources: 2
EBRT using a linear accelerator is the most common treatment for patients with stage III prostate cancer, and large series support its success in achieving local disease control and disease-free survival (DFS).[3,4] The results of radical prostatectomy in stage III patients are greatly inferior compared with results in patients with stage II cancer. Interstitial implantation of radioisotopes is technically difficult in large tumors.
The patient’s symptoms related to cancer, age, and coexisting medical illnesses should be considered before deciding on a therapeutic plan. In a series of 372 patients treated with radiation therapy and followed for 20 years, 47% eventually died of prostate cancer, but 44% died of intercurrent illnesses without evidence of prostate cancer.[4]
Sources: 4
Treatment Options for Stage III Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for patients with stage III prostate cancer include:
Sources: stage III prostate cancer
External-beam radiation therapy (EBRT) with or without hormonal therapy.
Sources: External-beam radiation therapy (EBRT) with or without hormonal therapy
Hormonal manipulations (with or without radiation therapy).
Sources: Hormonal manipulations (with or without radiation therapy)
Radical prostatectomy with or without EBRT.
Watchful waiting or active surveillance/active monitoring.
Sources: Watchful waiting or active surveillance/active monitoring
External-beam radiation therapy (EBRT) with or without hormonal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
EBRT alone,[3-7] luteinizing hormone-releasing hormone (LH-RH) agonist, or orchiectomy, in addition to EBRT, should be considered.[8-16] Definitive radiation therapy should be delayed until 4 to 6 weeks after transurethral resection to reduce the incidence of stricture.[17]
Hormonal therapy should be considered in conjunction with radiation therapy especially in men who do not have underlying moderate or severe comorbidities.[8,9] Several studies have investigated its use in patients with locally advanced disease.
Evidence (EBRT with or without hormonal therapy):
Although patients in the Radiation Therapy Oncology Group (RTOG) RTOG-9413 trial (NCT00769548) showed a 15% estimated risk of lymph node involvement and received whole-pelvic radiation therapy compared with prostate-only radiation therapy, overall survival (OS) and PSA failure rates were not significantly different.[18]; [19][Level of evidence B1]
Sources: RTOG-9413 · 18 · 19 · Level of evidence B1
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of an LH-RH agonist plus long-term flutamide (250 mg PO tid) with or without EBRT. Nineteen percent of the men had tumor stage T2, and 78% of the men had stage T3.[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer (T1b–T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of an LH-RH agonist plus long-term flutamide (250 mg PO tid) with or without EBRT. Nineteen percent of the men had tumor stage T2, and 78% of the men had stage T3.[20][Level of evidence A1]
At 10 years, both overall mortality (29.6% vs. 39.4%; 95% confidence interval [CI] for the difference, 0.8%–8.8%) and the prostate cancer-specific mortality (11.9% vs. 23.9%; 95% CI for the difference, 4.9%–19.1%) favored combined hormonal and radiation therapy.
Although flutamide might not be considered a standard hormonal monotherapy in the setting of T2 or T3 tumors, radiation therapy provided a DFS or tumor-specific survival advantage even though this monotherapy was applied. This analysis rests on the assumption that flutamide does not shorten life expectancy and cancer-specific survival. Radiation therapy was not delivered by current standards of dose and technique.
Another trial compared androgen deprivation therapy (ADT: an LH-RH agonist or orchiectomy) to ADT plus radiation therapy (65–69 Gy to the prostate by 4-field box technique, including 45 Gy to the whole pelvis, seminal vesicles, and external/internal iliac nodes unless the lymph nodes were histologically negative). This trial (NCIC CTG PR.3/MRC UKPRO7 [NCT00002633]) from the National Cancer Institute of Canada, randomly assigned 1,205 patients with high-risk (PSA >40 ng/mL or PSA >20 ng/mL and Gleason score ≥8), T2 (12%–13% of the patients), T3 (83% of the patients), and T4 (4%–5% of the patients) with clinical or pathologically staged N0, M0 disease.[21,22][Level of evidence A1]
Sources: NCIC CTG PR.3/MRC UKPRO7 · 21 · 22 · Level of evidence A1
Another trial compared androgen deprivation therapy (ADT: an LH-RH agonist or orchiectomy) to ADT plus radiation therapy (65–69 Gy to the prostate by 4-field box technique, including 45 Gy to the whole pelvis, seminal vesicles, and external/internal iliac nodes unless the lymph nodes were histologically negative). This trial (NCIC CTG PR.3/MRC UKPRO7 [NCT00002633]) from the National Cancer Institute of Canada, randomly assigned 1,205 patients with high-risk (PSA >40 ng/mL or PSA >20 ng/mL and Gleason score ≥8), T2 (12%–13% of the patients), T3 (83% of the patients), and T4 (4%–5% of the patients) with clinical or pathologically staged N0, M0 disease.[21,22][Level of evidence A1]
At a median follow-up of 8 years (maximum, 13 years), OS was superior in the ADT-plus-radiation therapy group (hazard ratio [HR]death, 0.77; 95% CI, 0.57–0.85, P = .001). The OS rate at 10 years was 55% for the ADT-plus-radiation therapy group versus 49% for the ADT-alone group.
Although radiation therapy had the expected bowel and urinary side effects, quality of life (QOL) was the same in each study group by 24 months and beyond.[23]
Sources: 23
The RTOG performed a prospective randomized trial (RTOG-8531) in patients with T3, N0, or any T, N1, M0 disease who received prostatic and pelvic radiation therapy and then were randomly assigned to receive immediate adjuvant goserelin or observation with administration of goserelin at time of relapse. In patients assigned to receive adjuvant goserelin, the drug was started during the last week of the radiation therapy course and was continued indefinitely or until signs of progression.[24][Level of evidence A1]
Sources: 24 · Level of evidence A1
The RTOG performed a prospective randomized trial (RTOG-8531) in patients with T3, N0, or any T, N1, M0 disease who received prostatic and pelvic radiation therapy and then were randomly assigned to receive immediate adjuvant goserelin or observation with administration of goserelin at time of relapse. In patients assigned to receive adjuvant goserelin, the drug was started during the last week of the radiation therapy course and was continued indefinitely or until signs of progression.[24][Level of evidence A1]
The actuarial 10-year OS rate for the entire population of 945 analyzable patients was 49% on the adjuvant arm versus 39% on the observation arm (P = .002). There was also an improved actuarial 10-year local failure rate (23% vs. 38%, P < .001).
A similar trial was performed by the European Organisation for Research and Treatment of Cancer (EORTC). Patients with T1, T2 (World Health Organization grade 3), N0–NX or T3, T4, N0 disease were randomly assigned to receive either pelvic/prostate radiation therapy or identical radiation therapy and adjuvant goserelin (with cyproterone acetate for 1 month) starting with radiation therapy and continuing for 3 years. The 401 patients available for analysis were followed for a median of 9.1 years.[10,25][Levels of evidence A1 and B1]
A similar trial was performed by the European Organisation for Research and Treatment of Cancer (EORTC). Patients with T1, T2 (World Health Organization grade 3), N0–NX or T3, T4, N0 disease were randomly assigned to receive either pelvic/prostate radiation therapy or identical radiation therapy and adjuvant goserelin (with cyproterone acetate for 1 month) starting with radiation therapy and continuing for 3 years. The 401 patients available for analysis were followed for a median of 9.1 years.[10,25][Levels of evidence A1 and B1]
The Kaplan-Meier estimates of OS rates at 10 years were 58.1% in the adjuvant goserelin arm and 39.8% in the radiation alone arm (P = .0004). Similarly, 10-year DFS rates (47.7% vs. 22.7%, P < .0001) and local control rates (94.0% vs. 76.5%, P < .001) favored the adjuvant arm.[10,25]
Two smaller studies, with 78 and 91 patients each, have shown similar results.[26,27]
The role of adjuvant hormonal therapy in patients with locally advanced disease has been analyzed by the Agency for Health Care Policy and Research (AHCPR; now the Agency for Healthcare Research and Quality). Randomized clinical trial evidence comparing radiation therapy with radiation therapy with prolonged androgen suppression (with an LH-RH agonist or orchiectomy) was evaluated in a meta-analysis. Most patients had more advanced disease, but patients with bulky T2b tumors were included in the study.[11][Level of evidence A1]
Sources: 11 · Level of evidence A1
The role of adjuvant hormonal therapy in patients with locally advanced disease has been analyzed by the Agency for Health Care Policy and Research (AHCPR; now the Agency for Healthcare Research and Quality). Randomized clinical trial evidence comparing radiation therapy with radiation therapy with prolonged androgen suppression (with an LH-RH agonist or orchiectomy) was evaluated in a meta-analysis. Most patients had more advanced disease, but patients with bulky T2b tumors were included in the study.[11][Level of evidence A1]
The meta-analysis found a difference in 5-year OS in favor of radiation therapy plus continued androgen suppression compared with radiation therapy alone (HR, 0.631; 95% CI, 0.479–0.831).[11]
Sources: 11
Additionally, the RTOG did a study (RTOG-8610) in patients with bulky local disease (T2b, T2c, T3, or T4), with or without nodal involvement below the common iliac chain: 456 men were randomly assigned to receive either radiation therapy alone or radiation therapy with androgen ablation, which was started 8 weeks before radiation therapy and continued for 16 weeks. This trial assessed only short-term hormonal therapy, not long-term therapy, as the studies analyzed by the AHCPR did.[12,28]
Additionally, the RTOG did a study (RTOG-8610) in patients with bulky local disease (T2b, T2c, T3, or T4), with or without nodal involvement below the common iliac chain: 456 men were randomly assigned to receive either radiation therapy alone or radiation therapy with androgen ablation, which was started 8 weeks before radiation therapy and continued for 16 weeks. This trial assessed only short-term hormonal therapy, not long-term therapy, as the studies analyzed by the AHCPR did.[12,28]
At 10 years, OS was not statistically significantly different; however, disease-specific mortality rates (23% vs. 36%) and DFS rates (11% vs. 3%) favored the combined treatment arm.[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
A subset analysis of the RTOG-8610 trial and the RTOG-8531 trial that involved 575 patients with T3, N0, M0 disease indicated that long-term hormones compared with short-term hormones resulted in improved biochemical DFS and cause-specific survival.[29]
Sources: 29
This finding was confirmed by RTOG-9202 (NCT00767286), which reported that radiation therapy plus 28 months of androgen deprivation resulted in longer 10-year disease-specific survival rates (23% vs. 13%; P < .0001) but not OS rates (53.9% vs. 51.6%; P = .36).[13]
This finding was confirmed by RTOG-9202 (NCT00767286), which reported that radiation therapy plus 28 months of androgen deprivation resulted in longer 10-year disease-specific survival rates (23% vs. 13%; P < .0001) but not OS rates (53.9% vs. 51.6%; P = .36).[13]
An unplanned post-hoc subgroup analysis found increased OS with longer androgen deprivation (28 months vs. 4 months) (45% vs. 32%; P = .0061) in men with high-grade cancers and Gleason scores of 8 through 10.
In a randomized, prospective clinical trial, 18 months of androgen suppression with an LH-RH agonist appears to have provided results that were similar to 36 months with respect to OS and disease-specific survival.[30][Level of evidence A1] In the trial, 630 men with stage II to stage IVA cancer (clinical stage T3–T4, or PSA >20 ng/ml, or Gleason score >7) received 70 Gy of radiation in 35 fractions alone plus a total of either 18 or 36 months of goserelin acetate.
Sources: 30 · Level of evidence A1
In a randomized, prospective clinical trial, 18 months of androgen suppression with an LH-RH agonist appears to have provided results that were similar to 36 months with respect to OS and disease-specific survival.[30][Level of evidence A1] In the trial, 630 men with stage II to stage IVA cancer (clinical stage T3–T4, or PSA >20 ng/ml, or Gleason score >7) received 70 Gy of radiation in 35 fractions alone plus a total of either 18 or 36 months of goserelin acetate.
With a median follow-up of 9.4 years, OS was nearly identical in each study arm (62% at 10 years; HRdeath, 1.02; 95% CI, 0.81–1.29, P = .8), as was prostate cancer–specific survival (HRprostate death, 0.95; 95% CI, 0.58–1.55, P = .8).
Global quality of life was nearly identical on both study arms, but sexual activity and interest in sex was moderately better in the 18-month arm.[30][Level of evidence A3]
Sources: 30 · Level of evidence A3
Likewise, a meta-analysis of seven randomized controlled trials comparing early hormonal treatment (adjuvant or neoadjuvant) with deferred hormonal treatment (LH-RH agonists and/or antiandrogens) in patients with locally advanced prostate cancer, whether treated by prostatectomy, radiation therapy, or watchful waiting or active surveillance/active monitoring, showed improved overall mortality for patients receiving early treatment (relative risk, 0.86; 95% CI, 0.82–0.91).[31][Level of evidence A1]
Sources: 31 · Level of evidence A1
The duration of neoadjuvant hormonal therapy has been tested in a randomized trial (TROG 96.01 [ACTRN12607000237482]) involving 818 men with locally advanced (T2b, T2c, T3, and T4) nonmetastatic cancer treated with radiation therapy (i.e., 66 Gy in 2 Gy daily fractions to the prostate and seminal vesicles but not including regional lymph nodes). In an open-label design, patients were randomly assigned to radiation therapy alone, 3 months of neoadjuvant androgen deprivation therapy (NADT) (goserelin 3.6 mg subcutaneously each month plus flutamide 250 mg PO tid) for 2 months before and during radiation, or 6 months of NADT for 5 months before and during radiation.[14][Level of evidence A1]
Sources: 14 · Level of evidence A1
The duration of neoadjuvant hormonal therapy has been tested in a randomized trial (TROG 96.01 [ACTRN12607000237482]) involving 818 men with locally advanced (T2b, T2c, T3, and T4) nonmetastatic cancer treated with radiation therapy (i.e., 66 Gy in 2 Gy daily fractions to the prostate and seminal vesicles but not including regional lymph nodes). In an open-label design, patients were randomly assigned to radiation therapy alone, 3 months of neoadjuvant androgen deprivation therapy (NADT) (goserelin 3.6 mg subcutaneously each month plus flutamide 250 mg PO tid) for 2 months before and during radiation, or 6 months of NADT for 5 months before and during radiation.[14][Level of evidence A1]
After a median follow-up of 10.6 years, there were no statistically significant differences between the radiation-alone group and the radiation plus 3 months of NADT group.
However, the 6-month NADT arm showed better prostate cancer-specific mortality and overall mortality than radiation alone; 10-year all-cause mortality 29.2% versus 42.5% (HR, 0.63; 95% CI, 0.48–0.83, P = .0008).
The duration of neoadjuvant hormonal therapy was tested in another trial (RTOG-9910 [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason score 7, and PSA <20; or T1b–1c, Gleason score 8–10, and PSA <20) and no evidence of metastases. The men were randomly assigned to receive short-course neoadjuvant–androgen suppression (an LH-RH agonist plus bicalutamide or flutamide for 8 weeks before and 8 weeks during radiation therapy) or long-course neoadjuvant–androgen suppression (28 weeks before and 8 weeks during radiation therapy). Both groups received 70.2 Gy radiation in 39 daily fractions to the prostate and 46.8 Gy to the iliac lymph nodes.[32][Level of evidence A1]
Sources: RTOG-9910 · 32 · Level of evidence A1
The duration of neoadjuvant hormonal therapy was tested in another trial (RTOG-9910 [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason score 7, and PSA <20; or T1b–1c, Gleason score 8–10, and PSA <20) and no evidence of metastases. The men were randomly assigned to receive short-course neoadjuvant–androgen suppression (an LH-RH agonist plus bicalutamide or flutamide for 8 weeks before and 8 weeks during radiation therapy) or long-course neoadjuvant–androgen suppression (28 weeks before and 8 weeks during radiation therapy). Both groups received 70.2 Gy radiation in 39 daily fractions to the prostate and 46.8 Gy to the iliac lymph nodes.[32][Level of evidence A1]
After a median of 9.4 years, 10-year prostate-specific mortality, the primary end point, was low in both study arms: 5% versus 4% (HR, 0.81; 95% CI, 0.48–1.39).[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
No statistically significant differences in overall mortality or in locoregional disease progression were found.[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
There was also no apparent differential effect of androgen suppression duration among any of the risk-group subsets.
Hormonal manipulations (with or without radiation therapy)
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Hormonal manipulations (orchiectomy or LH-RH agonists) may be used in the treatment of stage III prostate cancer.[33][Level of evidence A1]
Sources: 33 · Level of evidence A1
Some data suggest that the efficacy of orchiectomy or LH-RH agonists may be enhanced by the addition of abiraterone acetate in men with locally advanced tumors. In the randomized, open-label, STAMPEDE trial (NCT00268476) trial, 1,917 men (about 95% newly diagnosed; about 50% had metastatic disease and about 50% had locally advanced or node-positive disease) were treated with ADT alone or ADT plus abiraterone acetate (1,000 mg PO qd) and prednisolone (5 mg PO qd).[34] Local radiation therapy was mandated after 6 to 9 months for men with node-negative nonmetastatic disease and optional for those with node-positive nonmetastatic disease. Hormone therapy was curtailed at 2 years or until progression. Radiation therapy was planned in about 40% of the study participants.
With a median follow-up of 40 months, the 3-year OS rate was 83% in the abiraterone study group compared with 76% in the ADT-only study group (HRdeath, 0.63; 95% CI, 0.52–0.76; P < .001).[34][Level of evidence A1] Although there was no clear evidence of heterogeneity in relative treatment differences in metastatic disease versus nonmetastatic disease, absolute differences were much smaller in men with nonmetastatic disease and not statistically significant, perhaps because of the short follow-up (HRdeath, 0.75; 95% CI, 0.49–1.18).
Sources: 34 · Level of evidence A1
The main additional differences in toxicity associated with abiraterone compared with ADT alone were hypertension (5% vs. 1%), mild increase in blood aminotransferase levels (6% vs. <1%), and respiratory disorders (5% vs. 2%).
Antiandrogen monotherapy has also been evaluated in men with locally advanced prostate cancer as an alternative to castration.
Evidence (nonsteroidal antiandrogen monotherapy vs. surgical or medical castration):
A systematic evidence review compared nonsteroidal antiandrogen monotherapy with surgical or medical castration from 11 randomized trials in 3,060 men with locally advanced, metastatic, or recurrent disease after local therapy.[35] Use of nonsteroidal antiandrogens as monotherapy decreased OS and increased the rate of clinical progression and treatment failure.[35][Level of evidence A1]
Sources: 35 · 35 · Level of evidence A1
Evidence (orchiectomy vs. LH-RH agonist):
In a randomized equivalence study involving 480 men with locally advanced (T3 and T4) disease, those who were treated with castration had a median OS of 70 months, whereas those treated with bicalutamide (150 mg qd) had a median OS of 63.5 months (HR, 1.05; 95% CI, 0.81–1.36); these results failed to meet the prespecified criteria for equivalence.[36][Level of evidence A1]
Sources: 36 · Level of evidence A1
Immediate versus deferred hormonal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In patients who are not candidates for or who are unwilling to undergo radical prostatectomy or radiation therapy, immediate hormonal therapy has been compared with deferred treatment (i.e., watchful waiting or active surveillance/active monitoring with hormonal therapy at progression).
Evidence (immediate vs. deferred hormonal therapy):
A randomized trial looked at immediate hormonal treatment (orchiectomy or LH-RH agonist) versus deferred treatment in men with locally advanced or asymptomatic metastatic prostate cancer.[33][Level of evidence A1]
Sources: 33 · Level of evidence A1
A randomized trial looked at immediate hormonal treatment (orchiectomy or LH-RH agonist) versus deferred treatment in men with locally advanced or asymptomatic metastatic prostate cancer.[33][Level of evidence A1]
Initial results showed better OS and prostate cancer-specific survival with the immediate treatment. This subsequently lost statistical significance as was recorded in abstract form.[37]
Sources: 37
The incidence of pathological fractures, spinal cord compression, and ureteric obstruction were also lower in the immediate treatment arm.
In another trial, 197 men with stage III or stage IV prostate cancer were randomly assigned to receive bilateral orchiectomy at diagnosis or at the time of symptomatic progression (or at the time of new metastases that were deemed likely to cause symptoms).[38][Level of evidence A1]
Sources: 38 · Level of evidence A1
In another trial, 197 men with stage III or stage IV prostate cancer were randomly assigned to receive bilateral orchiectomy at diagnosis or at the time of symptomatic progression (or at the time of new metastases that were deemed likely to cause symptoms).[38][Level of evidence A1]
No statistically significant difference in OS was seen over a 12-year period of follow-up.
In the EORTC-30891 trial (NCT01819285), 985 patients newly diagnosed with prostate cancer, stage T0–4, N0–2, M0, and a median age of 73 years were randomly assigned to receive androgen deprivation, either immediately or on symptomatic disease progression. The study was designed to demonstrate the noninferiority of deferred treatment as compared with immediate treatment in relation to OS.[39][Level of evidence A1]
Sources: EORTC-30891 · 39 · Level of evidence A1
In the EORTC-30891 trial (NCT01819285), 985 patients newly diagnosed with prostate cancer, stage T0–4, N0–2, M0, and a median age of 73 years were randomly assigned to receive androgen deprivation, either immediately or on symptomatic disease progression. The study was designed to demonstrate the noninferiority of deferred treatment as compared with immediate treatment in relation to OS.[39][Level of evidence A1]
At a median follow-up of 7.8 years, approximately 50% of the patients in the deferred treatment group had initiated androgen deprivation.
The median OS in the immediate treatment group was 7.4 years, and, in the deferred treatment group, it was 6.5 years, corresponding to a mortality HR of 1.25 (95% CI, 1.05–1.48), which failed to meet the criteria for noninferiority.
Continuous versus intermittent hormonal therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
When used as the primary therapy for patients with stage III or stage IV prostate cancer, androgen suppression with hormonal therapy is usually given continuously until there is disease progression. Some investigators have proposed intermittent androgen suppression as a strategy to attain maximal tumor cytoreduction followed by a period without therapy to allow tumor repopulation by hormone-sensitive cells. Theoretically, this strategy might provide tumor hormone responsiveness for a longer period. An animal model suggested that intermittent androgen deprivation (IAD) could prolong the duration of androgen dependence of hormone-sensitive tumors.[40]
Sources: 40
Evidence (continuous vs. intermittent hormonal therapy):
A systematic review of 15 randomized trials that compared continuous androgen deprivation versus IAD therapy for patients with advanced or recurrent prostate cancer found no significant difference in OS, which was reported in eight of the trials (HR, 1.02; 95% CI, 0.93–1.11); prostate–cancer-specific survival, reported in five of the trials (HR, 1.02; 95% CI, 0.87–1.19); or progression-free survival, reported in four of the trials (HR, 0.94; 95% CI, 0.84–1.05). The meta-analysis fulfilled prespecified criteria for noninferiority of OS (upper bound of 1.15 for the HRdeath, 1.15).[41][Level of evidence A1] However, of the 15 trials, all but one had an unclear or high risk of bias according to prespecified criteria.
Sources: 41 · Level of evidence A1
A systematic review of 15 randomized trials that compared continuous androgen deprivation versus IAD therapy for patients with advanced or recurrent prostate cancer found no significant difference in OS, which was reported in eight of the trials (HR, 1.02; 95% CI, 0.93–1.11); prostate–cancer-specific survival, reported in five of the trials (HR, 1.02; 95% CI, 0.87–1.19); or progression-free survival, reported in four of the trials (HR, 0.94; 95% CI, 0.84–1.05). The meta-analysis fulfilled prespecified criteria for noninferiority of OS (upper bound of 1.15 for the HRdeath, 1.15).[41][Level of evidence A1] However, of the 15 trials, all but one had an unclear or high risk of bias according to prespecified criteria.
There was minimal difference in patient-reported QOL, but most trials found better physical and sexual functioning in patients in the IAD arms.
Radical prostatectomy with or without EBRT
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radical prostatectomy may be used with or without EBRT (in highly selected patients).[42] Because about 40% to 50% of men with clinically organ-confined disease are found to have pathological extension beyond the prostate capsule or surgical margins, the role of postprostatectomy adjuvant radiation therapy has been studied.
Sources: 42
Evidence (radical prostatectomy with or without EBRT):
In a randomized trial of 425 men with pathological T3, N0, M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[43,44]
In a randomized trial of 425 men with pathological T3, N0, M0 disease, postsurgical EBRT (60–64 Gy to the prostatic fossa over 30–32 fractions) was compared with observation.[43,44]
After a median follow-up of about 12.5 years, OS was better in the radiation therapy arm; HRdeath, 0.72 (95% CI, 0.55–0.96; P = .023). The 10-year estimated survival rates were 74% in the radiation therapy arm and 66% in the control arm.
The 10-year estimated metastasis-free survival rates were 73% and 65% (P = .016).[44][Level of evidence A1]
Sources: 44 · Level of evidence A1
Short-term complication rates were substantially higher in the radiation therapy group: overall complications were 23.8% versus 11.9%, rectal complications were 3.3% versus 0%, and urethral stricture was 17.8% versus 9.5%.
Watchful waiting or active surveillance/active monitoring
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Careful observation without further immediate treatment may be used in the treatment of stage III prostate cancer.[48,49]
Asymptomatic patients of advanced age or with concomitant illness may warrant consideration of careful observation without immediate active treatment.[50-52] Watch and wait, observation, expectant management, and active surveillance/active monitoring are terms indicating a strategy that does not employ immediate therapy with curative intent. For more information, see the Treatment Option Overview for Prostate Cancer section.
Sources: 50 · 52 · Treatment Option Overview for Prostate Cancer
Treatment of Symptoms
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Because many stage III patients have urinary symptoms, control of symptoms is an important consideration in treatment. The following modalities may be used to improve local control of disease and subsequent symptoms:
Radiation therapy.
Sources: Radiation therapy
Hormonal manipulation.
Sources: Hormonal manipulation
Palliative surgery (transurethral resection of the prostate [TURP]).
Interstitial implantation combined with EBRT.
Alternative forms of radiation therapy (under clinical evaluation).
Ultrasound-guided percutaneous cryosurgery (under clinical evaluation).
Radiation therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Hormonal manipulation
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Hormonal manipulations effectively used as initial therapy for prostate cancer include:
Orchiectomy.
Leuprolide or other LH-RH agonists (e.g., goserelin) in daily or depot preparations. These agents may be associated with tumor flare.
Estrogens (diethylstilbestrol [DES] is no longer available in the United States).
Nonsteroidal antiandrogens (e.g., flutamide, nilutamide, and bicalutamide) or steroidal antiandrogen (e.g., cyproterone acetate).
A meta-analysis of randomized trials comparing various hormonal monotherapies in men with stage III or stage IV prostate cancer (predominantly stage IV) came to the following conclusions:[53][Level of evidence A1]
Sources: 53 · Level of evidence A1
The OS at 2 years using any of the LH-RH agonists was similar to treatment with orchiectomy or 3 mg qd of DES (HR, 1.26; 95% CI, 0.92–1.39).
Survival rates at 2 years were similar or worse with nonsteroidal antiandrogens compared with orchiectomy (HR, 1.22; 95% CI, 0.99–1.50).
Treatment withdrawals, used as a surrogate for adverse effects, occurred less with LH-RH agonists (0%–4%) than with nonsteroidal antiandrogens (4%–10%).
Interstitial implantation combined with EBRT
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Interstitial implantation combined with EBRT is being used in selected T3 patients, but little information is available.[54]
Sources: 54
Alternative forms of radiation therapy
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Alternative forms of radiation therapy are being employed in clinical trials.
A randomized trial from the RTOG reported improved local control and survival with mixed-beam (neutron/photon) radiation therapy compared with standard photon radiation therapy.[55]
Sources: 55
A subsequent randomized study from the same group compared fast-neutron radiation therapy with standard photon radiation therapy. Local-regional control was improved with neutron treatment, but no difference in OS was seen, although follow-up was shorter in this trial. Fewer complications were seen with the use of a multileaf collimator.[56]
Sources: 56
Proton-beam radiation therapy is also under investigation.[57]
Sources: 57
Ultrasound-guided percutaneous cryosurgery
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Ultrasound-guided percutaneous cryosurgery is under clinical evaluation.
Cryosurgery is a surgical technique under development that involves destruction of prostate cancer cells by intermittent freezing of the prostate with cryoprobes, followed by thawing.[58][Level of evidence C1]; [59]; [60][Level of evidence C3] Cryosurgery is less well established than standard prostatectomy, and long-term outcomes are not as well established as with prostatectomy or radiation therapy. Serious toxic effects include bladder outlet injury, urinary incontinence, sexual impotence, and rectal injury. The technique of cryosurgery is under development. Impotence is common. The frequency of other side effects and the probability of cancer control after 5 years of follow-up have varied among reporting centers, and series are small compared with surgery and radiation therapy.[59,60]
Sources: 58 · Level of evidence C1 · 59 · 60 · Level of evidence C3 · 59 · 60
Treatment of Stage IV Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Overview
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Stage IV prostate cancer is defined by the American Joint Committee on Cancer's TNM (tumor, node, metastasis) classification system:[1]
Sources: 1
Stage IVA
Any T, N1, M0, any prostate-specific antigen (PSA), any Gleason.
Stage IVB
Any T, N0, M1, any PSA, any Gleason.
Extraprostatic extension with microscopic bladder neck invasion (T4) is included with T3a.
Treatment selection depends on the following factors:
Age.
Coexisting medical illnesses.
Symptoms.
The presence of distant metastases (most often bone) or regional lymph node involvement only.
The most common symptoms originate from the urinary tract or from bone metastases. Palliation of symptoms from the urinary tract with transurethral resection of the prostate (TURP) or radiation therapy and palliation of symptoms from bone metastases with radiation therapy or hormonal therapy are an important part of the management of these patients. Bisphosphonates may also be used for the management of bone metastases.[2]
Sources: 2
Treatment Options for Stage IV Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for patients with stage IV prostate cancer include:
Sources: stage IV prostate cancer
Hormonal manipulations.
Sources: Hormonal manipulations
Hormonal manipulations with chemotherapy.
Bisphosphonates.
Sources: Bisphosphonates
External-beam radiation therapy (EBRT) with or without hormonal therapy.
Sources: External-beam radiation therapy (EBRT) with or without hormonal therapy
Palliative radiation therapy.
Sources: Palliative radiation therapy
Palliative surgery with TURP.
Sources: Palliative surgery with TURP
Watchful waiting or active surveillance/active monitoring.
Sources: Watchful waiting or active surveillance/active monitoring
Radical prostatectomy with immediate orchiectomy (under clinical evaluation).
Triangle